James T. Dalton, Ph.D.

PERSONAL INFORMATION:

Address: Home - [redacted]

Office - University of Alabama
Office of Academic Affairs
254 Rose Administration
Box 870114
Tuscaloosa, AL 35487

Contact Information: [redacted]

EMPLOYMENT:

University of Alabama, Tuscaloosa, AL
2020-present Executive Vice President and Provost, Professor of Translational Science and Medicine, College of Community Health Sciences and Professor of Chemical and Biological Engineering, College of Engineering

University of Michigan [AAU], Ann Arbor, MI
2014 – 2020 Dean and Professor of Pharmaceutical Sciences, College of Pharmacy

GTx, Inc., Memphis, TN
2005 – 2014 Chief Scientific Officer (2011) and Vice President of Preclinical Research and Development

The Ohio State University [AAU], Columbus, OH
2007 – 2008 Professor, College of Pharmacy, Division of Pharmaceutics, Part-time (20%) appointment.
2005 – 2007 Entrepreneurial Leave-of-Absence from The Ohio State University (50% appointment)
2006 - 2007 Kimberly Professor, College of Pharmacy, Division of Pharmaceutics
2004 – 2007 Professor, College of Pharmacy, Division of Pharmaceutics
2002 – 2005 Chair, College of Pharmacy, Division of Pharmaceutics
2000 – 2004 Tenured Associate Professor, College of Pharmacy, Division of Pharmaceutics

University of Tennessee [AAU], Memphis, TN
1997 – 2000 Associate Professor, College of Pharmacy, Department of Pharmaceutical Sciences. Tenured 1998.
1992 - 1997 Assistant Professor, College of Pharmacy, Department of Pharmaceutical Sciences

The Ohio State University [AAU], Columbus, OH
1991 - 1992 Senior Research Associate and Lecturer, College of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry
1986 - 1990 Graduate Teaching and Research Associate, College of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry

EDUCATION:

1991-1992	Postdoctoral Fellow, The Ohio State University, Columbus, OH. Division of Pharmaceutics and Pharmaceutical Chemistry
1986-1990	Ph.D. in Pharmaceutics and Pharmaceutical Chemistry, The Ohio State University, Columbus, OH Dissertation: "Pharmacokinetic and Pharmacodynamic Implications of Drug Absorption from the Urinary Bladder"
1981-1986	B.S. in Pharmacy (Magna Cum Laude), University of Cincinnati, Cincinnati, OH
1981	Diploma, Franklin High School, Franklin, OH

LICENSURE:

Registered Pharmacist, State of Ohio, License #03-2-16408, inactive status

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS:

American Association for the Advancement of Science – Pharmaceutical Sciences Section Steering Group (2021-2025)
American Association of Colleges of Pharmacy
American Association of Pharmaceutical Scientists
National Academy of Medicine

HONORS AND AWARDS:

2023	Nicholas Bodor Distinguished Lectureship, University of Florida, College of Pharmacy
2019	Elected as Member of the National Academy of Medicine
2019	Robert J. DeSalvo Distinguished Alumni Award, University of Cincinnati, College of Pharmacy
2018	Rho Chi Lecture Award, The Rho Chi Society presented at 2018 Annual Meeting of the American Pharmacists Association
2016	Fellow of the American Association for the Advancement of Science (AAAS)
2011	Jack L. Beal Post-Baccalaureate Alumni Award, The Ohio State University
2006	Fellow of the American Association of Pharmaceutical Scientists (AAPS)
2002	AAPS Meritorious Manuscript Award, Pharmaceutical Research, 17(7): 803-810, 2000.
2000	Student Government Association Executive Council (SGAEC) Excellence in Teaching Award, College of Pharmacy, University of Tennessee
1997	Student Government Association Executive Council (SGAEC) Excellence in Teaching Award, College of Graduate Health Sciences, University of Tennessee
1990	Benjamin Balshone Outstanding Graduate Student Award, The Ohio State University
1987 - 1990	Fellow of the American Foundation for Pharmaceutical Education
1986 - 1990	Academic Challenge Fellowship, Ohio State University, College of Pharmacy
1986	Kappa Psi Scholarship Honors Award, University of Cincinnati
1986	Outstanding Contribution Award, Student APhA, University of Cincinnati
1986	Bristol Award for Outstanding Achievement, University of Cincinnati
1985	Rho Chi Society, University of Cincinnati
1985	Plough Scholarship, University of Cincinnati
1981	Albert Voorheis Honors Scholarship, University of Cincinnati
1981	Mary Rowe Moore Admission with Distinction Award, University of Cincinnati

RESPONSIBILITIES and ACHIEVEMENTS AS PROVOST at ALABAMA:

- Chief academic officer overseeing teaching, research and service missions of 13 schools, colleges and related academic areas encompassing >2,000 faculty, >4,500 staff and >40,000 students in >70 undergraduate programs and >120 master's, educational specialist and doctoral programs. Budget ~ $1.2B.
- Direct reports include: Dean of Arts & Sciences, Dean of Business, Dean of Communication & Information Sciences, Dean of Community Health Sciences, Dean of Education, Dean of Engineering, Dean of Graduate School, Dean of Honors College, Dean of Human Environmental Sciences, Dean of Law, Dean of Libraries, Dean of Nursing, Dean of Social Work, Associate Provost for Academic Affairs, Associate Provost for Opportunities, Connections and Success, Associate Provost for Faculty Affairs, Associate Provost for Financial Affairs, Associate Provost for International Education & Global Outreach, Associate Provost for Teaching Innovation & Digital Education, Vice Provost & Chief Information Officer, Assistant Provost for Institutional Effectiveness, Associate Vice President & Executive Director of Enrollment Management, Executive Director of Institutional Research & Assessment, Executive Director of Center for Student Success and Executive Director of Shelby Institute for Policy & Leadership. Please see the organizational chart below.



- Successfully managed pandemic-related transitions of educational programs from face-to-face to online and hybrid learning – maximizing face-to-face and synchronous online learning while prioritizing faculty, staff and student health and safety. In Spring 2021 (one year into the pandemic), UA offered face-to-face instruction in over 80% of its undergraduate classes.
- Launched initiative to reduce undergraduate class sizes – increased percentage of classes with fewer than 20 students from 36% in Fall 2020 to 46% in Fall 2021 and 48% in Fall 2022 and Fall 2023.
- Evaluated programs and changed the administrative oversight of the Student Health Center (from Student Life to College of Community Health Sciences), the Bryant Museum (from College of Continuing Studies to Museums within the College of Arts & Sciences), and integrated Alabama Heritage magazine and the University of Alabama Press into University Libraries to gain operational efficiencies and align reporting structures.
- Charged faculty committee to re-envision UA's online educational programs. Reorganized College of Continuing Studies to Office of Teaching Innovation and Digital Education (OTIDE) within Office of Academic Affairs to gain operational efficiencies and launch the University's first center for teaching and learning (UA Teaching Academy; https://uateachingacademy.ua.edu/).

- Designed and launched inaugural Crimson Scholars First-Year Experience program for freshman Pell-grant recipients in 2021. Program organizes Pell-eligible Alabama resident undergraduate students into learning communities to provide support for academic success, career planning, one-on-one mentorship, peer mentorship, and social connections. Second-year retention for Crimson Scholars participants in the Fall 2023 cohort was 87.3% as compared to 80.8% for all Pell-grant recipients. There are 469 participants in the Fall 2024 cohort of the program.
- Launched the "Finish Strong" strategic recruit back campaign focused on un-enrolled students with 90+ credit hours in Spring 2021. UA's 6-year graduation rate for Pell grant recipients has risen 5% since implementation (59.5% for Fall 2020 cohort).
- Revised graduate education policies to: reduce required coursework (48 to 36 credit hours), develop a harmonized definition of doctoral candidacy, reduce fees for continued graduate enrollment, permit certain renewable contract faculty to serve on dissertation committees, and remove requirement for 6-year renewal of graduate faculty status.
- Hired new deans for: the School of Social Work (2020), College of Communication & Information Sciences (2022), College of Engineering (2022), Honors College (2023), School of Law (2023), Capstone College of Nursing (2023), and College of Education (2024).
- Led search for Vice President of Research and Economic Development (2024).
- Launched Academic Program Review Council to review all academic programs on an 8-year cycle. Completed reviews of Departments of Biological Sciences (2021), Psychology (2021), Religious Studies (2022), Geological Sciences (2022), Political Science (2022), Kinesiology (2023), Educational Studies in Psychology Research Methods and Counseling (ESPRMC; 2023), Art & Art History (2023), Electrical and Computer Engineering (2023), Chemical and Biological Engineering (2023), Construction and Environmental Engineering (2023), Computer Science (2023), Nursing Sciences (2023), Consumer Sciences (2024), Metallurgical & Materials Engineering (2024), Mechanical Engineering (2024), Aerospace Engineering (2024), English (2024), Communicative Disorders (2024), Social Work (2024), History (2024), Health Science (2024), American Studies (2024), Anthropology (2024) and Criminology & Criminal Justice (2025).
- Led creation, campus-wide dissemination and discussion, and faculty consideration of a proposed new general education core curriculum for the University based on report/input from faculty task force and faculty senate in collaboration with Dean of College of Arts & Sciences. The new core reduces required core hours from 53-55 credit hours to 37-38 credit hours, adds a common first-year experience, allows for greater flexibility in humanities, literature, and fine arts, and adds a cultures & societies course, capstone experience, and experiential education requirement. A quorum (>1,000) of full-time University faculty approved the new core in a November 2022 faculty referendum.
- Thought leader in discussions regarding test-optional admissions with UAB and UAH provosts and presidents, UAS and Board of Trustees from fall 2020 to present.
- Leading implementation of the faculty-approved general education core curriculum for launch in Fall 2025 through structures of a General Education Implementation Steering Committee and 11 faculty-led sub-committees.
- Launched newly established Shelby Distinguished Faculty Program ($100M endowment) and Shelby Institute for Policy and Leadership ($20M endowment).
- Supported 60% increase in total sponsored awards in 4 years (2020=$168.4M to 2024=$269.9M) by making targeted investments in individual faculty, departments, and colleges, fostering culture of enhanced scholarship expectations, and creating faculty professional and career development opportunities in collaboration with VPs for research and deans.
- Worked collaboratively with Faculty Senate and Professional Staff Assembly on: (1) improvements to parental leave policy, (2) creation of faculty titles to better reflect duties and responsibilities of renewal contract faculty, (3) acquisition and renovation of new campus child care facility, (4) creation of UA Subvention Grant Program, and (5) creation of a comprehensive Faculty Professional Development program (https://facultyaffairs.ua.edu/).
- Oversaw successful reaffirmation of the University of Alabama's accreditation by the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC). Site visit February 2025. Quality Enhancement Plan entitled: Peer-led Engagement, Excellence, and Resilience through Supplemental instruction (PEERS).

RESPONSIBILITIES and ACHIEVEMENTS AS DEAN at MICHIGAN:

- Recognized as Michigan's top-rated dean (https://aec.umich.edu/results2020/deans-sorted.php) for five consecutive years during annual faculty surveys in which faculty were asked if they were "satisfied with the transparency of my school or college's administrative policies" or if they "have confidence in my dean's leadership overall".
- CEO Dean of #3 ranked US College of Pharmacy responsible for oversight of all academic, research, clinical, community engagement programs, and budget within decentralized budget model.
- Direct reports included: Senior Associate Dean of Faculty Affairs, Associate Dean of Clinical Affairs/Chief Pharmacy Officer for Michigan Medicine, Associate Dean for Pharmacy Innovation/Associate Chief Clinical Officer for Quality and Care Innovation for Michigan Medicine, Associate Dean for Research and Graduate Education, Assistant Dean for Co-Curriculum and Professional Development, Assistant Dean for Student Services and Admissions, Assistant Dean for Curriculum Assessment, Assistant Dean for Experiential Education, Assistant Dean of Diversity, Equity, and Inclusion, Chair of Department of Clinical Pharmacy, Chair of Department of Medicinal Chemistry, Chair Department of Pharmaceutical Sciences, and Chief Administrative Officer.
- Oversaw doubling of extramural research expenditures in 6 years and an improvement in USNWR ranking from #7 to #3 during my tenure as dean.
- Led development, faculty approval, and launch of the College's first new undergraduate program (Bachelor of Science in Pharmaceutical Sciences) in 2016.
- Led development, faculty approval, and launch of College's first and only master's degree program (MS in Integrated Pharmaceutical Sciences) in 2019.
- Exceeded capital campaign goal for College, raising almost $25M in new student scholarships, research endowments, professorships, and funds for a new building (approved by Board of Regents in May 2019). The UM College of Pharmacy has the largest endowment of any pharmacy school (~$130M).

ROLE at GTx:

- Leadership and direct supervision of all aspects of drug discovery, preclinical and product development, including drug discovery, medicinal chemistry, drug metabolism, analytical sciences, safety and toxicology assessment, pre-formulation, product development (CMC) teams at GTx. Group size between 35-50 people. Budget ~$15 million.
- Leadership of Intellectual Property team, including quarterly review meetings, interactions with internal and external patent counsel, annual GTx scientific meeting and publication strategy.
- Leadership and supervision of product development (CMC) activities from discovery through phase III development.
- Leadership and supervision of all Phase I studies, including single and multiple ascending dose studies, drug:drug interaction studies, disease impairment studies, absolute bioavailability studies, mass balance studies, bioequivalence studies, population pharmacokinetic modeling and thorough QT studies.
- Authorship of Phase I, Phase II and Phase III clinical protocols. Responsible for writing first draft of Phase I clinical protocols, collecting and integrating comments from biostatistics, clinical development, clinical operations, external consultants, finance, medical affairs, product development (CMC), regulatory affairs and safety.
- Identification and assessment of partners and vendors for ancillary services to support planned and ongoing clinical trials, including central laboratory services, immunohistochemistry and pathology, centralized CT and bone scan imaging, thromboembolic monitoring, bioanalytical, and cardiac monitoring.
- Liaison to external partners, including roles on Executive Steering Committee (member), Product Development Committee (clinical; chair and member), Research Steering Committee (chair and member) and business development teams (JP Morgan, BioAsia, major pharmaceutical companies).
- Representative to preclinical and clinical development (Phase I, Phase II, and Phase III) teams with external partners, including drug discovery, lead optimization, Phase I, Phase II, Phase III clinical trial design, protocol development (inclusion/exclusion criteria, primary and secondary efficacy and safety endpoints, clinical pharmacology).
- Medical affairs activities, scientific training of medical science liaisons, external continuing education, key opinion leader meetings, clinical trial investigator meetings, and consultation with medical experts.

- FDA and European (MPA, EMA, MHRA) regulatory interactions as preclinical and clinical pharmacology representative, including pre-IND meetings, end of Phase II meetings, pre-NDA meeting, scientific advice meetings and clinical hold responses.

PREVIOUS UNIVERSITY SERVICE:

College of Pharmacy, University of Tennessee

Member	Graduate Research Council Committee, 1993 to 2000
Member	Pre-Pharmacy Curriculum Subcommittee, 1994
Member	Curriculum Committee, 1994, 1995, 1996
Vice-Chair	Curriculum Committee, 1996, 1997
Representative	Curricular Reform Committee, AACP Institute, Williamsburg VA, 1996
Chair	Anatomy Curriculum Subcommittee, 1997
Member	Pharm.D./Ph.D. Program Review Committee, 1997
Advisor	Alpha Nu Chapter of Rho Chi Society, 1997 to 2000

University of Tennessee

Member	American Cancer Society Review Committee, 1994 to 2000
Member	Radiation Safety Committee, 1996 to 2000
Member	Animal Care and Use Committee, 1998 to 2000

College of Pharmacy, The Ohio State University

Member	Curriculum Committee, 2000 to 2002
Member	Pharm.D. Program Committee, 2000 to 2007
Member	Executive Committee, 2002 to 2005
Chair	Appointments, Promotion and Tenure Committee, 2006
Member	Comprehensive Cancer Center, 2000-2007

University of Michigan

Member	Provost's Academic Program Group, 2014 - 2020
Member	U-M Shared Services Center Governance Council, 2014-2018
Member	Chair (2016-2018), U-M Health Sciences Council, 2014 – 2020
Member	Chair (2015-2020), Executive Committee, Michigan Drug Discovery, 2014 – 2020
Member	Executive Committee, Biointerfaces Institute, 2014- 2020
Member	Search Committee for Chair of Department of Pharmacology, U-M Medical School, 2014-2015
Member	Search Committee for Dean of U-M School of Nursing, 2015-2016
Member	Executive Committee, Michigan Center for Therapeutic Innovation, 2016 – 2020
Member	Executive Committee, U-M Forbes Institute for Cancer Discovery. 2016 – 2020
Member	Executive Committee, Life Sciences Institute, 2016 – 2020
Member	Provost's Capital Projects Review Committee, 2016 – 2020
Member	U-M Translational Research Council, 2016 – 2020
Member	Search Committee for Chief Scientific Officer, U-M Medical School, 2016
Member	Biosciences Subcommittee, Provost's Academic Program Group, 2018 – 2020
Member	DEI Subcommittee, Provost's Academic Program Group, 2019 – 2020

PROFESSIONAL SERVICE:

Reviewer	Pharmaceutical Research, Journal of Pharmaceutical Sciences, British Journal of Clinical Pharmacology, Drug Metabolism and Disposition, Clinical Cancer Research, Journal of Medicinal Chemistry, Bioorganic and Medicinal Chemistry, Steroids, Pharmacogenetics, Journal of Clinical Endocrinology and Metabolism, Nature Medicine
Moderator	American Association of Pharmaceutical Scientists (AAPS) Southern Regional Discussion Group, Oxford, MS, May 1998
Reviewer	Oncological Sciences Initial Review Group, Special Emphasis Panel, Experimental Therapeutics 2 Study Section, National Institutes of Health, August 1998
Vice-Chair	Southern Regional Discussion Group, American Association of Pharmaceutical Scientists, Second Annual Meeting at Northeast Louisiana University, 1999
Chair	Southern Regional Discussion Group, American Association of Pharmaceutical Scientists, Third Annual Meeting at University of Tennessee, 2000
Chair	Publicity Committee, AAPS Midwest Regional Meeting, Rosemont Conference Ctr, Chicago IL, 2000.
Member	Study Section, SBIR/STTR Special Emphasis Panel, National Institutes of Health, Center for Scientific Review, Washington, DC, March 2000 and July 2000
Member	Study Section on Innovative Treatments, California Breast Cancer Research Program, San Francisco, CA, April 2000, 2001, and 2002
Member	Ad Hoc, Experimental Therapeutics 1 (ET1) Study Section, Center for Scientific Review, National Institutes of Health, Washington, DC, October 2000
Member	Ad Hoc, Xenobiotic and Nutrient Disposition and Absorption (XNDA) Study Section, Center for Scientific Review, National Institutes of Health, Washington, DC, June 2004
Member	Nuclear Receptor Program Project Study Section (ZDK1 GRB-C, M3), Center for Scientific Review, National Institutes of Health, Washington, DC, April 2005
Member	U54 Contraceptive Development Research Centers Program, RFA-HD-06-014 Study Section, ZHD1 DRG-H (53), Center for Scientific Review, Bethesda, MD April 2012
Member	Editorial Advisory Board, Pharmaceutical Research, November 2005-2020
Trustee	Pink Palace Museum, Memphis Museums, Inc., 2012- 2014
Reviewer	American Association for the Advancement of Science (AAAS), University of North Carolina Research Opportunities Initiative, January 2015
Vice Chair	Board of Directors, National Institute of Pharmaceutical Technology and Education (NIPTE), 2015-2018.
Member	Advisory Committee on Pharmaceutical Sciences, University of Washington, School of Pharmacy, Seattle, WA, January – June 2016
Moderator	American Association of Colleges of Pharmacy (AACP), 2016 Annual Meeting, Deans' Networking Session: Establishing and Sustaining Graduate Research Programs in Schools and Colleges of Pharmacy, Anaheim, CA, July 2016
Member	American Association of Colleges of Pharmacy (AACP), 2017 Council of Deans Nominations Committee
Chair	American Association of Colleges of Pharmacy (AACP) Pharmacy Curriculum Outcomes Assessment (PCOA) Task Force, March 2017-present
Member	American Association of Colleges of Pharmacy (AACP) Impact Task Force, October 2017-present.
Member	Accreditation Site Visit Team for Chapman University, Irvine, VA, Accreditation Council for Pharmacy Education (ACPE), April 16-18, 2018
Chair	Scientific Advisory Board, Partnership for Clean Competition, United States Anti-Doping Agency (USADA), 2018-present
Member	Board of Grants, American Foundation for Pharmaceutical Education (AFPE), 2018-present
Chair	Board of Directors, National Institute of Pharmaceutical Technology and Education (NIPTE), 2018-2020
Member -at-Large	Elected to four-year term as member-at-large of the Section of Pharmaceutical Sciences of the American Association for the Advancement of Science (AAAS), 2021-2025
Member	Forum on Drug Discovery, Development, and Translation, National Academy of Medicine, 2025-2027

CLINICAL TRIAL CONTRIBUTIONS:

Toremifene, A Selective Estrogen Receptor Modulator

- Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men with Prostate Cancer on Androgen Deprivation Therapy. Study Number: G300213, April 2010. IND Number: 63,763.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men with High Grade Prostatic Intraepithelial Neoplasia (PIN). Study Number: G300104, October 2004. IND Number: 59,302.

GTx-758, A Selective Estrogen Receptor Alpha Agonist

- Single Dose Relative Bioavailability and Food Effect Study of Multiple Tablet Formulations of GTx-758 in Healthy Adult Male Subjects. Study Number: G100704, October 2010. IND Number: 110,542.
- Double-Blind, Single-Dose Safety, Tolerability and Pharmacokinetic Study of GTx-758 in Healthy Adult Male Subjects. Study Number: G100701, January 2009. IND Number: 110,542.
- Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Effect Study of GTx-758 in Healthy Adult Male Subjects. Study Number: G100702, June 2009. IND Number: 110,542.
- Open Label, Dose Finding Study of the Effect of GTx-758 on Testosterone Levels in Men. Study Number: G200703, December 2009. IND Number: 110,542.
- Phase II, Open Label, Dose Finding Study of the Effect of GTx-758 on Total and Free Testosterone Levels in Men with Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist. Study Number: G200705, March 2011. IND Number: 110,542.
- Open Label Study of the Effect of GTx-758 on Serum PSA and Free Testosterone Levels in Men with Castration Resistant Prostate Cancer and Maintained on Androgen Deprivation Therapy. Study Number: G200707, January 2012. IND Number: 110,542.
- Phase II, Open Label, Loading and Maintenance Dose Finding Study of GTx-758 in Men with Prostate Cancer. Study Number: G200710, June 2011. IND Number: 110,542.
- Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men with Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy. Study Number: G200712, May 2012. IND Number: 110,542.

GTx-024 (Enobosarm), A Selective Androgen Receptor Modulator (SARM)

- Double-Blind, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of GTx-024 in Healthy Adult Male Subjects. MDS Pharma Service, Belfast, Ireland. Study Number: G100401, February 2006.
- Double-Blind, Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Effect Study of GTx-024 in Healthy Adult and Healthy Elderly Male Subjects. Study Number: G100402, February 2006.
- Double-Blind, Placebo Controlled, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of GTx-024 in Postmenopausal Females and Elderly Males. Study Number: G200501, March 2007.
- Double-Blind, Placebo-Controlled, Dose-Finding Study Of The Effect Of GTx-024 On Muscle Wasting (Cachexia) In Patients With Cancer. Study Number: G200502. IND Number 75,504. December 2007.
- A Randomized, Double-Blind, Placebo Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Efficacy of GTx-024 in Healthy Postmenopausal Women. Merck & Co., Protocol 003. IND Number 101,531, January 2008.
- Double-Blind, Multiple Dose and Divided Dose Safety and Tolerability Study of GTx-024 in Healthy Elderly Subjects. Study Number: G100503. June 2008.
- A Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-2866 in Healthy Postmenopausal Japanese Women. Merck & Co., Protocol 006. September 2009.
- Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy. Study Number: G300504, June 2011. IND Number 75,504.

- Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy. Study Number: G300505, June 2011. IND Number 75,504.
- Phase II, Open Label Study of the Effect of GTx-024 on Objective Response Rate (ORR) in Women with Metastatic Breast Cancer. Study Number G200801, May 2012, IND Number: 75,504.
- Pharmacokinetics and Absolute Bioavailability of GTx-024 in Men and Postmenopausal Women. Study Number: G100507, final protocol. IND Number 75,504.
- Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics of GTx-024. Study Number: G100508, January 2013. IND Number 75,504.
- Human Mass Balance Study of GTx-024. Study Number: G100509, March 2013. IND Number 75,504.
- Thorough QT Study of GTx-024. Study Number: G100510, draft protocol. IND Number 75,504.
- Effect of Severe Renal Impairment on Pharmacokinetics of GTx-024. Study Number: G100511, January 2013. IND Number 75,504.
- Effect of Ketoconazole (CYP3A4 Inhibitor) on the Pharmacokinetics of GTx-024. Study Number: G100512, final protocol. IND Number 75,504.
- Effect of Rifampin (CYP3A4 Inducer) on the Pharmacokinetics of GTx-024. Study Number: G100513, final protocol. IND Number 75,504.
- Pharmacokinetic Drug:Drug Interaction Study of GTx-024 and Celecoxib (CYP2C9 substrate). Study Number: G100514, final protocol. IND Number 75,504.
- Pharmacokinetic Drug:Drug Interaction Study of GTx-024 and Probenecid (UGT2B7). Study Number: G100515, final protocol. IND Number 75,504.
- Pharmacokinetic Drug:Drug Interaction Study of GTx-024 and Rosuvastatin (BCRP substrate). Study Number: G100515, final protocol. IND Number 75,504.

PEER-REVIEWED PUBLICATIONS (JOURNALS):

Google Scholar Metrics: 21,730 citations, H-index 78, i10-index 266

1. **Dalton JT**, Geuns ER, and Au JLS. High-Performance Liquid Chromatographic Determination of Mitomycin C in Rat and Human Plasma and Urine. Journal of Chromatography (Biomedical Applications), 495: 330-337, 1989.
2. Wientjes MG, **Dalton JT**, Badalament RA, Dasani BM, Drago JR, and Au JLS. A Method to Study Drug Concentration-Depth Profiles in Tissues: Mitomycin C in Dog Bladder Wall. Pharmaceutical Research, 8:168-173, 1991.
3. Au JLS, **Dalton JT**, and Wientjes MG. Evidence of Significant Absorption of Sodium Salicylate from Urinary Bladder of Rats. Journal of Pharmacology and Experimental Therapeutics, 258: 357-364, 1991.
4. Wientjes MG, **Dalton JT**, Badalament RA, Drago JR, and Au JLS. Bladder Wall Penetration of Intravesical Mitomycin C in Dogs. Cancer Research, 51: 4347-4354, 1991.
5. **Dalton JT**, Au JLS, Wientjes MG, and Badalament RA. Pharmacokinetics of Mitomycin C in Patients Undergoing Intravesical Therapy for Superficial Bladder Cancer. Cancer Research, 51: 5144-5152, 1991.
6. **Dalton JT**, Harrington MD, and Au JLS. Evidence of Significant Absorption of Antipyrine from Urinary Bladder of Rats. Journal of Pharmacology and Experimental Therapeutics, 260: 608-613, 1992.
7. **Dalton JT** and Au JLS. Specificity of Human Placental 5'-Nucleotidase: No Metabolism of 2',3'-dideoxyinosine. Journal of Drug Metabolism and Disposition, 21:544-546, 1993.
8. Yeh TK, **Dalton JT**, and Au JLS. High-Performance Liquid Chromatographic Determination of Pentamidine in Plasma. Journal of Chromatography (Biomedical Applications), 622: 255-61, 1994.
9. **Dalton JT** and Au JLS. Effect of Bladder Resorption on Pharmacokinetic Data Analysis. Journal of Pharmacokinetics and Biopharmaceutics, 22:183-205, 1994.
10. Miller DD, Zhang X, **Dalton JT**, Yao XT, Shukla P, and Hsu FL. Synthesis and Biological Activity of a Series of Conformationally Restricted Analogs 4-Substituted Imidazoles as α_2-Adrenergic Agonists. U.S. Army Chem. Res., Devel. and Engin. Ctr, Science on Chemical Defense Research, 1995.
11. Mukherjee A, Kirkovsky L, Yao XT, Yates CR, and **Dalton JT**. Enantioselective Binding of Casodex to the Androgen Receptor. Xenobiotica 26(2):117-122, 1996.
12. Han G, Israel M, Seshardi R, **Dalton JT**, and Sweatman TW. Pharmacology of N,N-Di(n-butyl) adriamycin-14-valerate in the Rat. Cancer Chemotherapy and Pharmacology, 37:472-478, 1996.
13. Hughes TA, Heimberg M, Wang X, Wilcox H, Hughes SM, Tolley EA, Desiderio DM, and **Dalton JT**. Comparative Lipoprotein Metabolism of Myristate, Palmitate, and Stearate in Normolipidemic Men. Metabolism, 45:1108-1118, 1996.
14. Donkor IO, Queener SF, and **Dalton JT**. Pentamidine Congeners. 4. DNA Binding Affinity and Anti-*Pneumocystis Carinii* Activity of Butamidine Analogues. Bioorganic and Medicinal Chemistry Letters, 6:1967-1970, 1996.
15. Zhang X, Yao XT, **Dalton JT**, Shams G, Lei L, Patil PN, Feller DR, Hsu FL, George C, and Miller DD. Medetomidine Analogs as α_2-Adrenergic Ligands. 2. Design, Synthesis, and Biological Activity of Conformationally Restricted Napthalene Derivatives of Medetomidine. Journal of Medicinal Chemistry, 39(15):3001-3013, 1996.
16. Zhang X, De Los Angeles JE, He MY, **Dalton JT**, Shams G, Lei L, Patil PN, Feller DR, Miller DD, and Hsu FL. Medetomidine Analogs as α_2-Adrenergic Ligands. 3. Synthesis and Biological Evaluation of a New Series of Medetomidine Analogs and Their Potential Binding Interactions with α_2-Adrenoceptors Involving a "Methyl Pocket". Journal of Medicinal Chemistry, 40(19):3014-3024, 1997.
17. **Dalton JT**, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD. Discovery of Nonsteroidal Androgens. Biochemical and Biophysical Research Communications, 244(1):1-4, 1998.
18. Kidd R, Blaisdell J, Straughn A, Meyer MC, Goldstein J, and **Dalton JT**. Pharmacokinetics of Phenytoin, Glipizide and Nifedipine in a Homozygous CYP2C9-Leu 359 Individual. Pharmacogenetics, 9:71-80, 1999.
19. **Dalton JT**, Golub AL, Zhou D, Mukherjee A, Young D and Meyer MC. Pharmacokinetics of Aminolevulinic Acid after Intravesical Dosing to Dogs. Pharmaceutical Research, 16(2):288-295, 1999.
20. Mukherjee A, Kirkovsky LI, Kimura Y, Marvel MM, Miller DD, and **Dalton JT**. Affinity Labeling of the Androgen Receptor with Nonsteroidal Chemoaffinity Ligands. Biochemical Pharmacology, 58: 1259-1267, 1999.

21. **Dalton JT**, Meyer MC, and Golub AL. Pharmacokinetics of Aminolevulinic Acid after Oral and Intravenous Dosing in Dogs. Drug Metabolism and Disposition, 27 (4):432-435, 1999.
22. Hovinga CA, Chicella MF, Rose DF, Eades SK, **Dalton JT**, and Phelps SJ. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. Annals of Pharmacotherapy, 33(5):579-84, 1999.
23. Zhou D, Lu Y, Steiner MS, and **Dalton JT**. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. Antimicrobial Agents and Chemotherapy, 44(10):2659-2663, 2000.
24. Brimer C, **Dalton JT**, Zhu Z, Schuetz J, Yasuda K, Vanin E, Relling MV, Lu Y, and Schuetz EG. Creation of Polarized Cells Co-Expressing CYP3A4, NADPH Ctyochrome P450 Reductase and MDR1/P-glycoprotein. Pharmaceutical Research, 17(7): 803-810, 2000. **Selected as AAPS Meritorious Manuscript for 2002.
25. Kirkovsky L, Mukherjee A, Yin D, **Dalton JT**, and Miller DD. Chiral Nonsteroidal Affinity Ligands for the Androgen Receptor. 1. Bicalutamide Analogs bearing Electrophilic Groups at the Aromatic Ring B. Journal of Medicinal Chemistry, 43: 581-590, 2000.
26. Lan LB, **Dalton JT**, and Schuetz EG. Mdr1 Limits CYP3A Metabolism In Vivo. Molecular Pharmacology, 58(4):863-869, 2000.
27. Yates CR, Vysokanov A, Mukherjee A, Ludden T, Tolley E, Meduri GU, and **Dalton JT**. Time variant increases in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. Journal of Clinical Pharmacology, 41:415-424, 2001.
28. Marhefka CA, Moore II BM, Bishop TC, Kirkovsky L, Mukherjee A, **Dalton JT**, Miller DD. Homology Modeling Using Multiple Molecular Dynamics Simulations and Docking Studies of the Human Androgen Receptor Ligand Binding Domain Bound to Testosterone and Nonsteroidal Ligands. Journal of Medicinal Chemistry, 44: 1729-1740, 2001.
29. Zhu Z, Bulgakov O, Scott SS, and **Dalton JT**. Recombinant Expression And Purification Of Human Androgen Receptor In A Baculovirus System. Biochemical and Biophysical Research Communications, 284:828-835, 2001.
30. Zhu Z, Becklin RR, Desiderio DM, and **Dalton JT**. Identification of a Novel Phosphorylation Site of the Human Androgen Receptor by Mass Spectrometry. Biochemical and Biophysical Research Communications, 284:836-844, 2001.
31. Zhu Z, Becklin RR, Desiderio DM, and **Dalton JT**. Mass Spectrometric Characterization of the Human Androgen Receptor Ligand-Binding Domain Expressed in Escherichia Coli. Biochemistry, 40:10756-10763, 2001.
32. **Dalton JT**, Straughn AB, Dickason DA, and Grandolfi GP. Predictive Ability of Level A In Vitro/In Vivo Correlation for RingCap Controlled Release Acetaminophen Tablets. Pharmaceutical Research, 18: 1729-1734, 2001.
33. **Dalton JT**, Yates CR, Yin D, Straughn AB, Marcus SL, Golub AL, and Meyer MC. Clinical Pharmacokinetics of 5-Aminolevulinic Acid in Healthy Volunteers and Patients at High Risk for Recurrent Bladder Cancer. Journal of Pharmacology and Experimental Therapeutics, 301(2): 507-512, 2002.
34. Rogers TD, Gades NM, Kearbey JD, Virgous CK, and **Dalton JT**. Chronic Restraint Via Tail Immobilization in Mice: Effects on Corticosterone Levels and Other Physiologic Indices of Stress. Contemporary Topics in Laboratory Animal Science, 41(1):46-50, 2002.
35. He Y, Yin D, Perera MA, Kirkovsky L, Stourman N, **Dalton JT**, and Miller DD. Novel Nonsteroidal Ligands with High Affinity and Potent Functional Activity for the Human Androgen Receptor. European Journal of Medicinal Chemistry, 37: 619-634, 2002.
36. Yin D, He Y, Hong SS, Marhefka CA, Stourman N, Kirkovsky L, Miller DD, and **Dalton JT**. Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor. Molecular Pharmacology, 63:211-223, 2003.
37. Yin D, Xu H, He Y, Kirkovsky L, Miller DD, and **Dalton JT**. Pharmacology, Pharmacokinetics and Metabolism of Acetothiolutamide, A Novel Nonsteroidal Agonist for the Androgen Receptor. Journal of Pharmacology and Experimental Therapeutics, 304(3):1323-1333, 2003.
38. Yin D, Gao W, Kearbey JD, Xu H, Chung K, Miller DD, and **Dalton JT**. Pharmacodynamics of Selective Androgen Receptor Modulators. Journal of Pharmacology and Experimental Therapeutics, 304(3):1334-1340, 2003.

39. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, **Dalton JT**, and Swaan PW. Structural Determinants of P-glycoprotein-Mediated Transport of Glucocorticoids. Pharmaceutical Research, 20: 1794-1803, 2003.
40. Wu Z, Gao W, Phelps M, Wu D, Miller DD, and **Dalton JT**. The Favorable Effects of Weak Acids on Negative-Ion Electrospray Mass Spectrometry. Analytical Chemistry, 76(3):839-847, 2004.
41. Kearbey JD, Gao W, Chung K, Miller DD, and **Dalton JT**. Pharmacokinetics of a Novel Selective Androgen Receptor Modulator in Rats. Xenobiotica, 34 (3): 273-280, 2004.
42. Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, Bohl CE, **Dalton JT**, and Miller DD. Design and Synthesis of Novel Selective Androgen Receptor Modulators: Toward in vivo Metabolic Stability. Journal of Medicinal Chemistry, 47(4):993-998, 2004.
43. Liu Y, Kim BO, Kao C, Jung C, **Dalton JT**, and He JJ. Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa, is a negative regulator of androgen receptor (AR) transcription activation. Journal of Biological Chemistry, 279 (21): 21766-21783, 2004.
44. Phelps MA, Foraker AB, Gao W, **Dalton JT**, and Swaan PW. A Novel Rhodamine-Riboflavin Conjugate Probe Exhibits Distinct Fluorescence Resonance Energy Transfer that Enables Riboflavin Trafficking and Subcellular Localization Studies. Molecular Pharmaceutics, 1(4):257-266, 2004.
45. Bohl CE, Chang C, Mohler ML, Miller DD, Swaan PW, and **Dalton JT**. A Ligand-Based Approach to Identify Quantitative Structure-Activity Relationships for the Androgen Receptor. Journal of Medicinal Chemistry, 47(15):3765-3776, 2004.
46. Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, and **Dalton JT**. Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator (SARM), the 5{alpha}-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia (BPH). Endocrinology, 145(12): 5420-5428, 2004.
47. Gududuru V, Hurh E, Durgham GG, Hong SS, Sardar VM, Xu H, **Dalton JT**, and Miller DD. Synthesis and Biological Evaluation of Novel Cytotoxic Phospholipids for Prostate Cancer. Bioorganic and Medicinal Chemistry Letters, 14(19): 4919-4923, 2004.
48. Gududuru V, Hurh E, **Dalton JT**, and Miller DD. Synthesis and Antiproliferative Activity of 2-Aryl-4-Oxo-Thiazolidin-3-Yl-Amides for Prostate Cancer. Bioorganic and Medicinal Chemistry Letters, 14(21): 5289-5293, 2004.
49. Nair VA, Mustafa SM, Mohler ML, Fisher SJ, **Dalton JT**, and Miller DD. Synthesis of Novel Iodo Derived Bicalutamide Analogs. Tetrahedron Letters, 45: 9475-9477, 2004.
50. Chen J, Hwang DJ, Bohl CE, Miller DD, and **Dalton JT**. A Selective Androgen Receptor Modulator (SARM) for Hormonal Male Contraception. Journal of Pharmacology and Experimental Therapeutics, 312(2): 546-553, 2005.
51. Gududuru V, Hurh E, **Dalton JT**, and Miller DD. Discovery of 2-Arylthiazolidine-4-carboxylic acid Amides as a New Class of Cytotoxic Agents for Prostate Cancer. J Med Chem. 48(7):2584-2588, 2005.
52. Nair VA, Mustafa SM, Mohler ML, Fisher SJ, **Dalton JT**, and Miller DD. Synthesis of irreversibly binding bicalutamide analogs for imaging studies. Tetrahedron Letters, 46:4821-4823, 2005.
53. Bohl CE, Gao W, Miller DD, Bell CE, and **Dalton JT**. Structural Basis for Antagonism and Resistance of Bicalutamide in Prostate Cancer. Proc Natl Acad Sci U S A. 102(17): 6201-6206, 2005.
54. Gududuru V, Hurh E, Sullivan J, **Dalton JT**, and Miller DD. SAR Studies of 2-Arylthiazolidine-4-carboxylic Acid Amides: A Novel Class of Cytotoxic Agents for Prostate Cancer. Bioorganic Medicinal Chemistry Letters, 15(18): 4010-4013, 2005.
55. Chen J, Kim J, and **Dalton JT**. Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators. Molecular Interventions, 5(3):173-188, 2005.
56. Kim J, Wu D, Hwang DJ, Miller DD, and **Dalton JT**. The 4-Para-Substituent of S-3-(Phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a Major Structural Determinant of In Vivo Disposition and Activity of Selective Androgen Receptor Modulators. Journal of Pharmacology and Experimental Therapeutics, 315(1):230-239, 2005.
57. Phelps MA, Foraker AB, Gao W, **Dalton JT**, and Swaan PW. A novel rhodamine-riboflavin conjugate probe exhibits distinct fluorescence resonance energy transfer that enables riboflavin trafficking and subcellular localization studies. Molecular Pharmaceutics, 1(4):257-66, 2005.

58. Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, and **Dalton JT**. Selective Androgen Receptor Modulator (SARM) Treatment Improves Muscle Strength and Body Composition, and Prevents Bone Loss in Orchidectomized Rats. Endocrinology, 146(11):4887-4897, 2005.
59. Bohl CE, Miller DD, Chen J, Bell CE, and **Dalton JT**. Structural Basis for Accomodation of Nonsteroidal Ligands in the Androgen Receptor. Journal of Biological Chemistry, 280(45):37747-37754, 2005.
60. Gao W, Bohl CE, and **Dalton JT**. Chemistry and structural biology of androgen receptor. Chemical Reviews, 105(9):3352-70, 2005.
61. Chen J, Hwang DJ, Chung K, Bohl CE, Fisher SJ, Miller DD, and **Dalton JT**. In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Endocrinology, 146(12):5444-54, 2005.
62. Segal S, Narayanan R, and **Dalton JT**. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opinion in Investigational Drugs. 15(4):377-87, 2006.
63. Taneja SS, Smith MR, **Dalton JT**, Raghow S, Barnette G, Steiner M, and Veverka KA. Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opinion in Investigational Drugs. 15(3):293-305, 2006.
64. Gao W, Johnston JS, Miller DD, and **Dalton JT**. Inter-Species Differences in Pharmacokinetics and Metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide: The Role of N-Acetyltransferase. Drug Metabolism and Disposition, 34(2):254-260, 2006.
65. Gao W, Wu Z, Bohl CE, Yang J, Miller DD, and **Dalton JT**. Characterization of the In vitro Metabolism of Selective Androgen Receptor Modulator (SARM) Using Human, Rat and Dog Liver Enzyme Preparations. Drug Metabolism and Disposition, 34(2):243-253, 2006.
66. Perera MA, yin D, Wu D, Chan KK, Miller DD, and **Dalton JT**. In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs. Drug Metabolism and Disposition, 34(10):1713-1721, 2006.
67. Wu D, Wu Z, Yang J, Nair VA, Miller DD, and **Dalton JT**. Pharmacokinetics and metabolism of a selective androgen receptor modulator (SARM) in rats--implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. Drug Metabolism and Disposition, 34(3):483-494, 2006.
68. Yang J, Bohl CE, Nair VA, Mustafa SM, Hong SS, Miller DD, and **Dalton JT**. Preclinical pharmacology of a nonsteroidal ligand for androgen receptor mediated imaging of prostate cancer. Journal of Pharmacology and Experimental Therapeutics, 317(1):402-408, 2006.
69. George TG, Johnsamuel J, Delfin DA, Yakovich A, Mukherjee M, Phelps MA, **Dalton JT**, Sackett DL, Kaiser M, Brun R, and Werbovetz KA. Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. Bioorganic and Medicinal Chemistry, 14(16):5699-5710, 2006.
70. Wu D, George TG, Hurh E, Werbovetz KA, and **Dalton JT**. Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150. Life Sciences, 79(11):1081-1093, 2006.
71. Guan N, Korukonda R, Hurh E, Schmittgen TD, Donkor IO, and **Dalton JT**. Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. International Journal of Oncology, . 29(3):655-663.
72. Gao W, Kim J, **Dalton JT**. Pharmacokinetics and Pharmacodynamics of Nonsteroidal Androgen Receptor Ligands. Pharmaceutical Research, 23(8):1641-1658, 2006.
73. Hwang DJ, Yang J, Xu H, Rakov IM, Mohler ML, **Dalton JT**, and Miller DD. Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorganic and Medicinal Chemistry, .14(19):6525-6538, 2006.
74. Wu Z, Xing X, Bohl CE, Wisler JW, **Dalton JT**, and Bell CE. Domain structure and DNA binding regions of beta protein from bacteriophage lambda. Journal of Biological Chemistry, 281(35):25205-25214., 2006.
75. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, and **Dalton JT**. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nature, Clinical Practice in Endocrinology and Metabolism, 2(3):146-159, 2006.
76. Korukonda R, Guan N, **Dalton JT**, Liu J, and Donkor IO. Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha-ketoamides. Journal of Medicinal Chemistry, 49(17):5282-5290, 2006.
77. Nair VA, Mustafa SM, Mohler ML, **Dalton JT**, and Miller DD.Synthesis of oxazolidinedione derived bicalutamide analogs . Tetrahedron Letters, 47 (23): 3953-3955, 2006.

78. Patil R, Li W, Ross CR, Kraka E, Cremer D, Mohler ML, **Dalton JT**, and Miller DD. Cesium fluoride and tetra-n-butylammonium fluoride mediated 1,4-N-O shiftof disubstituted phenyl ring of a bicalutamide derivative. Tetrahedron Letters, 47:3941-3944, 2006.
79. Byrd JC, Lin TS, **Dalton JT**, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, and Grever MR. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 109(2):399-404, 2007.
80. Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, and **Dalton JT**. Selective Androgen Receptor Modulator (SARM) Treatment Prevents Bone Loss and Reduces Body Fat in Ovariectomized Rats. Pharmaceutical Research, 24(2):328-335, 2007.
81. **Dalton JT**. Pharmacokinetics and Metabolism in Drug Design. Methods and Principles in Medicinal Chemistry. Volume 31. Second Revised Edition. By Dennis A. Smith, Han van de Waterbeemd, and Don K. Walker. Wiley-VCH, Weinheim, Germany. 2006. xix + 187 pp. 17.5 x 24.5 cm. ISBN 3527313680. Journal of Medicinal Chemistry, 14;49(25):7556-7557, 2006.
82. Bohl CE, Wu Z, Miller DD, Bell CE, and **Dalton JT**. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. Journal of Biological Chemistry, 282(18):13648-13655, 2007.
83. Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, Bloomston M, Gibbs S, Saif OH, **Dalton JT**, Chan KK, Schlom J, Martin EW Jr, and Sun D. Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49CH2 and Murine Antibody CC49 in Colorectal Cancer Patients. Journal of Clinical Pharmacology, 47(2):227-37, 2007.
84. Gao W and **Dalton JT**. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discovery Today, 12(5-6):241-248, 2007.
85. Gao W and **Dalton JT**. Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5α-reductase? Molecular Interventions, 7(1):10-13, 2007.
86. Li W, Wang Z, Gududuru V, Zbytek B, Slominski AT, **Dalton JT**, and Miller DD. Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Research, 27(2):883-888, 2007.
87. Mohler ML, Narayanan R, He Y, Miller DD and **Dalton JT**. Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors: Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 1, 103-118, 2007.
88. Sharifi N, Hamel E, Lill MA, Risbood P, Kane CT Jr, Hossain MT, Jones A, **Dalton JT**, and Farrar WL. A bifunctional colchicinoid that binds to the androgen receptor. Molecular Cancer Therapeutics, 6(8):2328-2336, 2007.
89. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, **Dalton JT**, Sexton PM, Zhang XK, and Abagyan R. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proceedings of the National Academy of Sciences, U S A. 104(29):11927-11932, 2007.
90. Li W, Lu Y, Wang Z, **Dalton JT**, and Miller DD. Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorganic & Medicinal Chemistry Letters, 17(15):4113-4117, 2007.
91. Lai JP, **Dalton JT**, and Knoell DL. Phosphatase and tensin homologue deleted on chromosome ten (PTEN) as a molecular target in lung epithelial wound repair. British Journal of Pharmacology, . 152(8):1172-1184, 2007.
92. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, **Dalton JT**, Muthusamy N, and Byrd JC. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 111(1):275-284, 2008.
93. Phelps MA, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JC, Lin TS, Grever MR, and **Dalton JT**. Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. Journal of Chromatography B, Analytical Technology in the Biomedical Life Sciences, 868(1-2):110-115, 2008
94. Chen J, Wang Z, Lu Y, **Dalton JT**, Miller DD, and Li W. Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. Bioorganic and Medicinal Chemistry Letters, 18(11):3183-3187, 2008.

95. Bohl CE, Wu Z, Chen J, Mohler ML, Yang J, Hwang DJ, Mustafa S, Miller DD, Bell CE, and **Dalton JT**. Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bioorganic and Medicinal Chemistry Letters, 18(20): 5567-5570. 2008.
96. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, and **Dalton JT**. Steroidal Androgens and Nonsteroidal, Tissue Selective Androgen Receptor Modulators (SARM), S-22, Regulate Androgen Receptor Function Through Distinct Genomic and Non-Genomic Signaling Pathways. Molecular Endocrinology, 22(11): 2448-2465, 2008.
97. Morgan RE, Ahn S, Nzimiro S, Fotie J, Phelps MA, Cotrill J, Yakovich AJ, Sackett DL, and **Dalton JT**, Werbovetz KA. Inhibitors of tubulin assembly identified through screening a compound library. Chemical Biology & Drug Design, 72(6):513-524, 2008.
98. Yang X, Zhao X, Phelps MA, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, and **Dalton JT**, Lee RJ. A novel liposomal formulation of flavopiridol. International Journal of Pharmaceutics, 365(1-2): 170-174, 2009.
99. Jones A, Chen J, Hwang DJ, Miller DD, and **Dalton JT**. Preclinical Characterization of a (S)-N-(4-Cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-Hydroxy-2-Methyl-Propanamide: A Selective Androgen Receptor Modulator for Hormonal Male Contraception. Endocrinology, 150(1): 385-395, 2009.
100. Li W, Hwang DJ, Cremer D, Joo H, Kraka E, Kim J, Ross CR 2nd, Nguyen VQ, **Dalton JT**, andMiller DD. Structure determination of chiral sulfoxide in diastereomeric bicalutamide derivatives. Chirality. 21(6): 578-583, 2009.
101. Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JC, **Dalton JT**, and Phelps MA. Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. Therapeutic Drug Monitoring, 5:620-627, 2008.
102. Johnston JS, Phelps MA, Blum KA, Blum W, Grever MR, Farley KL, and **Dalton JT**. Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci., 871(1):15-21, 2008.
103. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, and **Dalton JT**. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, 113(12):2637-45, 2009. PMID: 18981292
104. Narayanan R, Mohler ML, Bohl CE, Miller DD, and **Dalton JT**. Selective androgen receptor modulators in preclinical and clinical development. Nuclear Receptor Signaling. 6:e010, 2008. PMID: 19079612
105. Lu Y, Li CM, Wang Z, Ross CR 2nd, Chen J, **Dalton JT**, Li W, and Miller DD. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. Journal of Medicinal Chemistry, 52(6):1701-1711, 2009. PMID: 19243174
106. Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, **Dalton JT**, and Miller DD. Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit. Journal of Medicinal Chemistry, 52(12):3597-3617, 2009. PMID: 19432422
107. Kearbey JD, Gao W, Fisher SJ, Wu D, Miller DD, and **Dalton JT**. Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats. Pharmaceutical Research, 26(11):2471-2477, 2009. PMID: 19728047
108. Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, **Dalton JT**, and Byrd JC. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leukemia and Lymphoma, 50(12):1958-1963, 2009. PMID: 19860603
109. Yang J, Wu Z, Wu D, Darby MV, Hong SS, Miller DD, and **Dalton JT**. Pharmacokinetics, biodistribution and metabolism of a novel selective androgen receptor modulator designed for prostate cancer imaging. International Journal of Oncology, 36(1):213-222, 2010. PMID: 19956850
110. Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, **Dalton JT**, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, and Baiocchi RA. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 1(1):31-40, 2009. PMID: 20046572 [

111. Lu Y, Wang Z, Li CM, Chen J, **Dalton JT**, Li W, and Miller DD. Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorganic Medicinal Chemistry, 18(2):477-495, 2010. PMID: 20056548
112. Narayanan R, Yepuru M, Szafran AT, Szwarc M, Bohl CE, Young NL, Miller DD, Mancini MA, and **Dalton JT**. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Research, 70(2):842-51, 2010. PMID: 20068182
113. Mohler ML, Narayanan R, Coss CC, Hu K, He Y, Wu Z, Hong SS, Hwang DJ, Miller DD, and **Dalton JT**. Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indications. Expert Opinion in Therapeutic Patents. 20(4):507-534, 2010. PMID: 20302450
114. Ahn S, Hwang DJ, Barrett CM, Yang J, Duke CB 3rd, Miller DD, and **Dalton JT**. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Cancer Chemotherapy and Pharmacology. 67(2):293-304, 2011. PMID: 20383708
115. Jones A, Hwang DJ, Duke CB, He Y, Siddam A, Miller DD, and **Dalton JT**. Nonsteroidal Selective Androgen Receptor Modulators Enhance Female Sexual Motivation. Journal of Pharmacology and Experimental Therapeutics, Journal of Pharmacology and Experimental Therapeutics, 334(2):439-448, 2010. PMID: 20444881
116. Liu Q, Alinari L, Chen CS, Yan F, **Dalton JT**, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, and Muthusamy N. FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma. Clinical Cancer Research, 16(12):3182-3192, 2010. PMID: 20460491
117. Giddabasappa A, Bauler MN, Yepuru M, Chaum E, **Dalton JT**, and Eswaraka JR.17-β Estradiol protects ARPE-19 cells from oxidative stress through estrogen receptor-β. Investigative Ophthalmology and Vision Science. 51(10):5278-87, 2010. PMID: 20463317
118. Jones A, Hwang DJ, Narayanan R, Miller DD, and **Dalton JT**. Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology. 151(8):3706-3719, 2010. PMID: 20534726
119. Giddabasappa A, Bauler MN, Barrett CM, Coss CC, Wu Z, Miller DD, **Dalton JT**, and Eswaraka JR. GTx-822, an ER-β Selective Agonist protects Retinal Pigment Epithelium (ARPE-19) from Oxidative Stress by Activating MAPK and PI3-K Pathways. Investigative Ophthalmology and Vision Science. 51(11):5934-42, 2010. PMID: 20554624.
120. Yepuru M, Eswaraka J, Kearbey JD, Barrett CM, Raghow S, Veverka KA, Miller DD, and **Dalton JT**, Narayanan R. Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. Journal of Biological Chemistry, 285(41):31292-303, 2010. PMID: 20657011.
121. Li CM, Lu Y, Narayanan R, Miller DD, and **Dalton JT**. Drug metabolism and pharmacokinetics of 4-Substituted Methoxybenzoyl-Aryl-Thiazoles (SMART). Drug Metabolism and Disposition. 38(11):2032-2039, 2010. PMID: 20675405.
122. Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, **Dalton JT**, and Steiner MS. Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies. Annual Review of Medicine. 62:265-79, 2011. PMID: 20731602.
123. Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, and **Dalton JT** 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. International Journal of Oncology. 37(4):1023-1030, 2010. PMID: 20811725.
124. Li CM, Lu Y, Ahn S, Narayanan R, Miller DD, and **Dalton JT**. Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin. Journal of Mass Spectrometry. 45(10):1160-1166, 2010. PMID: 20814887.
125. Ahn S, Duke CB 3rd, Barrett CM, Hwang DJ, Li CM, Miller DD, and **Dalton JT**. I-387, a Novel Antimitotic Indole, Displays a Potent In Vitro and In Vivo Antitumor Activity with Less Neurotoxicity. Molecular Cancer Therapeutics. 9(11):2859-2868, 2010. PMID: 20829196.
126. Chen J, Wang Z, Li CM, Lu Y, Vaddady PK, Meibohm B, **Dalton JT**, Miller DD, and Li W. Discovery of Novel 2-Aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. Journal of Medicinal Chemistry. 53(20):7414-7427, 2010. PMID: 20919720
127. Thevis M, Gerace E, Thomas A, Beuck S, Geyer H, Schlörer N, Kearbey JD, **Dalton JT**, and Schänzer W. Characterization of in vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23

and in vivo comparison to post-administration canine urine specimens. Drug Testing and Analysis. Nov-Dec;2(11-12):589-98, 2010. PMID: 20967890

128. Narayanan R, Jiang J, Gusev Y, Jones A, Kearbey JD, Miller DD, Schmittgen TD, and **Dalton JT**. MicroRNAs are mediators of androgen action in prostate and muscle. PLoS One. 5(10):e13637, 2010. PMID: 21048966
129. Ni W, Ji J, Dai Z, Papp A, Johnson AJ, Ahn S, Farley KL, Lin TS, **Dalton JT**, Li X, Jarjoura D, Byrd JC, Sadee W, Grever MR, and Phelps MA. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One. 5(11):e13792, 2010. PMID: 21072184.
130. Li CM, Wang Z, Lu Y, Ahn S, Narayanan R, Kearbey JD, Parke DN, Li W, Miller DD, and **Dalton JT**. Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. Cancer Research. 71(1):216-24, 2011. PMID: 21084278.
131. Ahn S, Kearbey JD, Li CM, Duke CB, Miller DD, and **Dalton JT**. Biotransformation of a Novel Antimitotic Agent, I-387, by Mouse, Rat, Dog, Monkey, and Human Liver Microsomes and In Vivo Phamacokinetics in Mice. Drug Metabolism and Disposition. 39(4):636-643, 2011. PMID: 21233217.
132. Coss CC, Bohl CE, and **Dalton JT**. Cancer cachexia therapy: a key weapon in the fight against cancer. Current Opinion in Clinical Nutrition and Metabolic Care. 14(3):268-273, 2011. PMID: 21415732.
133. Duke CB, Jones A, Bohl CE, **Dalton JT**, and Miller DD. Unexpected Binding Orientation of Bulky-B-Ring Anti-Androgens and Implications for Future Drug Targets. Journal of Medicinal Chemistry. 54(11):3973-3976, 2011. PMID: 21506597
134. Lu Y, Li CM, Wang Z, Chen J, Mohler ML, Li W, **Dalton JT**, and Miller DD. Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents. Journal of Medicinal Chemistry. 54(13):4678-4693, 2011. PMID: 21557538
135. Liang SB, Yang XZ, Trieu Y, Li Z, Zive J, Leung-Hagesteijn C, Wei E, Zozulya S, Coss CC, **Dalton JT**, Fantus IG, and Trudel S. Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134. Clinical Cancer Research. 17(14):4693-4704, 2011 Jun 1. PMID: 21632854
136. Thevis M, Thomas A, Möller I, Geyer H, **Dalton JT**, and Schänzer W. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls. Rapid Communications in Mass Spectrometry. 25(15):2187-95, 2011. PMID: 21710598
137. Kim J, Peraire C, Solà J, Johanning KM, **Dalton JT**, and Veverka KA. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica. 41(10):851-862, 2011. PMID: 21726172
138. Li CM, Chen J, Lu Y, Narayanan R, Parke DN, Li W, Ahn S, Miller DD, and **Dalton JT**. Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-Aryl-Thiazole (SMART) and 2-Aryl-4-Benzoyl-Imidazole (ABI) for Improving Oral Bioavailability. Drug Metabolism and Disposition. 39(10):1833-1839, 201. PMID: 21742898
139. Chen J, Li CM, Wang J, Ahn S, Wang Z, Lu Y, **Dalton JT**, Miller DD, and Li W. Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. Bioorganic & Medicinal Chemistry. 2011 Aug 15;19(16):4782-4795, 2011. PMID: 21775150
140. **Dalton JT**, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, and Steiner MS. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. Journal of Cachexia Sarcopenia and Muscle. 2(3):153-161, 2011. PMID: 22031847
141. Coss CC, Bauler M, Narayanan R, Miller DD, and **Dalton JT**. Alanine Aminotransferase Regulation by Androgens in Non-Hepatic Tissues. Pharmaceutical Research. 29(4):1046-1056, 2012. PMID: 22167351.
142. Coss CC, Jones A, Parke DN, Narayanan R, Barrett CM, Kearbey JD, Veverka KA, Miller DD, Morton RA, Steiner MS, and **Dalton JT**. Preclinical Characterization of a Novel Diphenyl Benzamide Selective ERα Agonist for Hormone Therapy in Prostate Cancer. Endocrinology. 153(3):1070-1081, 2012. PMID:22294742.
143. Wang Z, Chen J, Wang J, Ahn S, Li CM, Lu Y, Loveless VS, **Dalton JT**, Miller DD, and Li W. Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis. Pharmaceutical Research. 29(11):3040-3052, 2012. PMID: 22410804.
144. Yang J, Ahn S, Wu Z, Hwang DJ, Miller DD, and **Dalton JT**. Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer. International Journal of Oncology. 41(1):337-44, 2012. PMID: 22576690.

145. Mohler ML, Coss CC, Duke CB 3rd, Patil SA, Miller DD, and **Dalton JT**. Androgen receptor antagonists: a patent review (2008-2011). Expert Opinion in Therapeutic Patents. 22(5):541-65, 2012. PMID:22583332.
146. Giddabasappa A, Eswaraka JR, Barrett CM, Bauler MN, Wu Z, Yepuru M, Miller DD, and **Dalton JT**. β-LGND2, an ERβ Selective Agonist Inhibits Pathological Retinal Neovascularization. Investigative Ophthalmology and Vision Science. 53(8):5066-5075, 2012. PMID:22714897.
147. Li CM, Lu Y, Chen J, Costello TA, Narayanan R, Dalton MN, Snyder LM, Ahn S, Li W, Miller DD, and **Dalton JT**. Orally Bioavailable Tubulin Antagonists for Paclitaxel-Refractory Cancer. Pharmaceutical Research 29(11):3053-3063, 2012. PMID:22760659.
148. Chen JJ, Ahn S, Wang J, Lu Y, **Dalton JT**, Miller DD, and Li W. Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents. Journal of Medicinal Chemistry. 55(16):7285-7289, 2012. PMID:22783954.
149. Kim J, Coss CC, Barrett CM, Mohler ML, Bohl CE, Li CM, He Y, Veverka KA, and **Dalton JT**. Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen. International Journal of Cancer. 132(6):1475-85, 2012. PMID:22915089.
150. Swanson HI, Wada T, Xie W, Renga B, Zampella A, Distrutti E, Fiorucci S, Kong B, Thomas AM, Guo GL, Narayanan R, Yepuru M, **Dalton JT**, and Chiang JY. Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metabolism and Disposition. 41(1):1-11, 2013. PMID:23043185.
151. Dobs AS, Boccia RV, Croot CC, Gabrail NY, and **Dalton JT**, Hancock ML, Johnston MA, Steiner MS Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncology. 14(4):335-345, 2013. PMID:23499390
152. Xiao M, Ahn S, Wang J, Chen J, Miller DD, **Dalton JT**, and Li W. Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties. Journal of Medicinal Chemistry. 56(8):3318-29, 2013. PMID:23547728.
153. Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, **Dalton JT**, Devine SM, Grever MR, and Phelps MA. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clinical Pharmacokinetics. 52(8):705-12, 2013. PMID:23588536
154. Pedram A, Razandi M, Korach KS, Narayanan R, **Dalton JT**, and Levin ER. ERβ Selective Agonist Inhibits Angiotensin-Induced Cardiovascular Pathology in Female Mice. Endocrinology 154:4352-64, 2013. PMID:23970786
155. Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, **Dalton JT**, and Narayanan R. Steroidogenic Enzyme AKR1C3 is a Novel Androgen Receptor-Selective Coactivator That Promotes Prostate Cancer Growth. Clinical Cancer Research. 19(20):5613-25, 2013. PMID:23995860
156. Kim J, Wang R, Veverka KA, and **Dalton JT**. Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats. Xenobiotica. 43(11):993-1009, 2013. PMID:24074268.
157. Kim J, Coss CC, and **Dalton JT**. Effect of para halogen modification of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides on metabolism and clearance. Archives of Pharmacal Research 37:1464-76, 2014. PMID:24105418
158. Pedram A, Razandi M, Narayanan R, **Dalton JT**, McKinsey TA, and Levin ER. Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Molecular Biology of the Cell. 2013 Oct 23. [Epub ahead of print] PMID:24152730
159. **Dalton JT**, Taylor RP, Mohler ML, and Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Current Opinion in Supportive and Palliative Care. Dec;7(4):345-51, 2013. PMID: 24189892
160. Park K, **Dalton JT**, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS, and Rubin MA. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Journal of Clinical Oncology. Jan 20;32(3):206-11, 2014. PMID: 24297949
161. Narayanan R, Yepuru M, Coss CC, Wu Z, Bauler MN, Barrett CM, Mohler ML, Wang Y, Kim J, Snyder LM, He Y, Levy N, Miller DD, and **Dalton JT**. Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation. PLoS One. Dec 26;8(12):e83380, 2013. PMID: 24386191

162. Coss CC, Jones A, Hancock ML, Steiner MS, and **Dalton JT**. Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian Journal of Andrology. Mar-Apr;16(2):256-61, 2014. PMID: 24407183
163. Coss CC, Jones A, and **Dalton JT**. Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer. Steroids. Nov;90:94-100, 2014. PMID: 24945109
164. Yu EY, Getzenberg RH, Coss CC, Gittelman MM, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Hancock ML, Smith J, **Dalton JT**, and Steiner MS. Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer. European Urology. Jun 24. pii: S0302-2838(14)00532-6, 2014. [Epub ahead of print] PMID: 2496897
165. Narayanan R, Ahn S, Cheney MD, Yepuru M, Miller DD, Steiner MS, and **Dalton JT**. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One. Jul 29;9(7):e103202, 2014. PMID: 25072326
166. Lu Y, Chen J, Wang J, Li CM, Ahn S, Barrett CM, **Dalton JT**, Li W, and Miller DD. Design, synthesis, and biological evaluation of stable colchicine binding site tubulin inhibitors as potential anticancer agents. Journal of Medicinal Chemistry. Sep 11;57(17):7355-66, 2014. PMID: 25122533
167. Hosoya K, Couto CG, London CA, Kisseberth WC, Phelps MA, and **Dalton JT**. Comparison of High-Dose Intermittent and Low-Dose Continuous Oral Artemisinin in Dogs With Naturally Occurring Tumors. Journal of the American Animal Hospital Association. 50(6):390-395, 2014. PMID: 25251432
168. Coss CC, Jones A, and **Dalton JT**. Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Investigational New Drugs. 34(4):458-467, 2016. PMID: 27105861
169. Crawford J, Prado CM, Johnson MA, Gralia RJ, Taylor RP, Hancock ML, and **Dalton JT**. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Current Oncology Reports. 18(6):37 (pages 1-11), 2016. PMID: 27138015
170. Ponnusamy S, Tran QT, Harvey I, Smallwood HS, Thiyagarajan T, Banerjee S, **Dalton JT**, Sullivan RD, Miller DD, Bridges D, and Narayanan R. Pharmacological Activation of Estrogen Receptor-β (ER-β) Increases Mitochondrial Function, Energy Expenditure, and Brown Adipose Tissue, FASEB J. 2016 Oct 12. pii: fj.201600787RR; PMID: 27733447.
171. Narayanan R and **Dalton JT**. Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. Cancers. 8(12):1-17, 2016. PMID: 27918430.
172. **Dalton JT**. The Long and Winding Road for Selective Androgen Receptor Modulators. British Journal of Clinical Pharmacology 83(10):2131-2133, 2017. PMID: 28621446
173. Narayanan R, Coss CC, and **Dalton JT**. Development of Selective Androgen Receptor Modulators (SARMs). Molecular and Cellular Endocrinology 465:134-142, 2018. PMID: 28624515
174. Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, **Dalton JT**, Miller DD, and Narayanan R. Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer. Cancer Research 77(22):6282-98, 2017. PMID: 28978635
175. Arnst KE, Wang Y, Hwang DJ, Xue Y, Costello T, Hamilton D, Chen Q, Yang J, Park F, **Dalton JT**, Miller DD, and Li W. A potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance. Cancer Research. 78(1):265-277, 2018. PMID: 2918047
176. Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, **Dalton JT**, Corey E, Plymate SR, Haffner MC, Mostaghel EA, and Nelson PS. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. Journal of Clinical Investigation. 131(10):146777, 2021. PMID: 33998604
177. Crawford J, Prado CM, Gralla RJ, Barnette G, **Dalton JT**, and Steiner MS. Enobosarm, a Selective Androgen Receptor Modulator (SARM) for the Prevention and Treatment of Muscle Wasting in Patients with Advanced Lung Cancer: Results from Two Randomized, Double-Blind, Placebo-Controlled, International Phase 3 Trials with Different Chemotherapy Regimens (POWER 1 and 2 Clinical Trials). Submitted 2025.

BOOK CHAPTERS:

1. Lawrence WH and **Dalton JT**. Tumor Induction. In: *Handbook of Biomaterials Evaluation: Scientific, Technical and Clinical Testing of Implant Materials*. von Recum AF (Ed.), Taylor and Francis, New York, NY, Chapter 17, 1999.
2. Miller DD, Brueggemeier RW, and **Dalton JT**. Adrenocorticoids. In: *Principles of Medicinal Chemistry, 5th Edition.* Foye WO, Lemke Tl, and Williams DA (Eds.), Williams and Wilkins, Baltimore, MD, 2002.
3. Miller DD, Brueggemeier RW, and **Dalton JT**. Sex Hormones. In: *Principles of Medicinal Chemistry, 5th Edition.* Foye WO, Lemke Tl, and Williams DA (Eds.), Williams and Wilkins, Baltimore, MD, 2002.
4. **Dalton JT** and Meyer MC. Bioavailability of Drugs and Bioequivalence. In: *Encyclopedia of Pharmaceutical Technology. 2nd edition*. Swarbrick J and Boylan JC (Eds.), Marcel Dekker, New York, NY, 2002.
5. **Dalton JT** and Yates CR. Bioavailability of Drugs and Bioequivalence. In: *Encyclopedia of Pharmaceutical Technology. 3rd edition*. Swarbrick J and Boylan JC (Eds.), Taylor and Francis, New York, NY, 2006.
6. Miller DD, Brueggemeier RW, and **Dalton JT**. Adrenocorticoids. In: *Foye's Principles of Medicinal Chemistry, Sixth Edition*. Lemke TL, Williams DA, Roche VF, and Zito SW (Eds.), Lippincott, Williams and Wilkins, New York, NY, 2007.
7. Miller DD, Brueggemeier RW, and **Dalton JT**. Men's Health. In: *Foye's Principles of Medicinal Chemistry, Sixth Edition*. Lemke TL, Williams DA, Roche VF, and Zito SW (Eds.), Lippincott, Williams and Wilkins, New York, NY, 2007.
8. Mohler ML, Bohl CE, Narayanan R, He Y, Hwang DJ, **Dalton JT**, Miller DD. Nonsteroidal Tissue-selective Androgen Receptor Modulators. In: *Nuclear Receptors as Drug Targets*. Edited by Eckhard Ottow and Hilmar Weinmann, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2008.
9. **Dalton JT** and Gao W. Androgen Receptor. In: *Nuclear Receptors Current Concepts and Future Challenges.* Edited by Christopher M. Bunce and Moray J. Campbell, Springer, 2010.
10. Miller DD, Brueggemeier RW, and **Dalton JT**. Adrenocorticoids. In: *Foye's Principles of Medicinal Chemistry, Seventh Edition*. Lemke TL, Williams DA, Roche VF, and Zito SW (Eds.), Lippincott, Williams and Wilkins, New York, NY, 2011.
11. Miller DD, Brueggemeier RW, and **Dalton JT**. Men's Health. In: *Foye's Principles of Medicinal Chemistry, Seventh Edition*. Lemke TL, Williams DA, Roche VF, and Zito SW (Eds.), Lippincott, Williams and Wilkins, New York, NY, 2011.
12. Coss CC and **Dalton JT**. Selective Androgen Receptor Modulators (SARMs) as Improved Anabolic Therapy for Women. In: *Estrogen Action and Women's Health.* Edited by V. Craig Jordan. World Scientific, New Jersey, 2012.
13. Narayanan R and **Dalton JT**. Selective Estrogen Receptor Modulators (SERMs) and Selective Androgen Receptor Modulators (SARMs). In: *Nuclear Receptors: From Structure to the Clinic.* Edited by Iain J. McEwan and Raj Kumar. Springer, New York, 2015.
14. Mohler M, Narayanan R, and **Dalton JT**. Drugs Used to Treat Inflammatory and Corticosteroid Deficiency Disorders. In: *Foye's Principles of Medicinal Chemistry, Eighth Edition*. Lemke TL, Williams DA, Roche VF, and Zito SW (Eds.), Lippincott, Williams and Wilkins, New York, NY, 2018.
15. Whetstone J, Mohler M, Narayanan R, and **Dalton JT**. Drugs Used to Advance Men's and Women's Health. In: *Foye's Principles of Medicinal Chemistry, Eighth Edition*. Lemke TL, Williams DA, Roche VF, and Zito SW (Eds.), Lippincott, Williams and Wilkins, New York, NY, 2018.
16. Mohler M and **Dalton JT**. Modulation of the Androgen Receptor Axis. In: *Burger's Medicinal Chemistry, Drug Discovery and Development, Eighth Edition.* John Wiley & Sons, Inc., Hoboken, NJ, 2019.
17. Mohler M, Narayanan R, and **Dalton JT**. Drugs Used to Treat Inflammatory and Corticosteroid Deficiency Disorders. In: *Foye's Principles of Medicinal Chemistry, Ninth Edition*. Lemke TL, Williams DA, Roche VF, and Zito SW (Eds.), Lippincott, Williams and Wilkins, New York, NY, 2025.
18. Mohler M, Narayanan R, and **Dalton JT**. Drugs Used to Advance Men's and Women's Health. In: *Foye's Principles of Medicinal Chemistry, Ninth Edition*. Lemke TL, Williams DA, Roche VF, and Zito SW (Eds.), Lippincott, Williams and Wilkins, New York, NY, 2025.

MEETING ABSTRACTS AND PRESENTATIONS:

1. **Dalton JT**, Wientjes MG, Au JLS, Badalament RA, Nesbitt JA, and Drago JR. Pharmacokinetics of Intravesical Mitomycin C in Bladder Cancer Patients. Proc. Am. Assoc. Cancer Res., 30:245 (976), 1989.
2. Wientjes, MG, Badalament RA, Drago JR, Nesbitt JA, **Dalton JT**, Smith JJ, and Au JLS. Bladder Absorption and Pharmacokinetics of Mitomycin C (MMC) in Trans-Urethral Resection Patients. Proc. Am. Urol. Assoc., 1989.
3. **Dalton JT**, Au JLS, Wientjes MG, Badalament RA, and Drago JR. Disposition of Mitomycin C in Intravesical Therapy. Proc. Am. Assoc. Cancer Res., 31:427 (2536), 1990.
4. Wientjes MG, Au JLS, Badalament RA, **Dalton JT**, and Drago JR. Bladder Wall Penetration of Intravesical Mitomycin C. Proc. Am. Assoc. Cancer Res., 31:427 (2537), 1990.
5. **Dalton JT**, Wientjes MG, and Au JLS. Evidence of Significant Bladder Absorption of Drugs in Rats. Pharmaceutical Res., 8(10):S255, 1991.
6. Dalton, JT and Au JLS. Chemosensitivity of Human Bladder Cancer Cells in Monolayer and 3-Dimensional Collagen Gel Cultures. Proc. Am. Assoc. Cancer Res., 33: 555 (3320), 1992.
7. **Dalton JT** and Au JLS. Effects of Bladder Resorption on Pharmacokinetic Data Analysis. Pharmaceutical Res., 9(10), S312, 1992.
8. **Dalton JT** and Au JLS. No Metabolism of 2',3'-Dideoxyinosine in Human Placenta. Proc. Am. Assoc. Cancer Res., 34:281 (1672), 1993.
9. **Dalton JT**, Wientjes MG, and Au JLS. Toxic Interaction of 2',3'-Dideoxyinosine and Allopurinol. Proc. Am. Assoc. Cancer Res., 34:281 (1673), 1993.
10. Yeh TK, **Dalton JT**, and Au JLS. High-Performance Liquid Chromatographic Determination of Pentamidine in Biological Specimens. Pharmaceutical Res., 10(10):S55, 1993.
11. **Dalton JT**, Wilkins PK, Yao XT, Hwang PTR, Golub AL, and Meyer MC. Pharmacokinetics and Bioavailability of 5-AminoLevulinic Acid in Dogs. Pharmaceutical Res., 11(10):S383, 1994.
12. Mukherjee A, Kirkovsky L, Yates CR, Yao XT, Miller DD, and **Dalton JT**. Enantioselective Androgen Receptor Binding of Casodex. Pharmaceutical Res., 12(9):S378, 1995.
13. **Dalton JT**, Yao XT, and Crom WR. Schedule-Dependent In Vivo Efficacy of Etoposide in Immunodeficient Mice Bearing Human Acute Lymphoblastic Leukemia.Pharmaceut.Res.,12(9):S337 1995.
14. Kirkovsky L, Mukherjee A, **Dalton JT**, and Miller DD. Approaches to Irreversible Non-Steroidal Chiral Antiandrogens. Southeast Regional Amer. Chem. Soc. Mtg., Memphis, TN, 1995.
15. Donkor IO, Yao XT, and **Dalton JT**. Geometric Isomerism. Its Effect on the Anti-Pneumocystis Carinii Activity of Pentamidine Congeners. National. Am. Chem. Soc. Mtg., 1995.
16. Wolfe MS, Harry-O'kuru RE, and **Dalton JT**. Synthesis and Evaluation of 2'-C-Methylribonucleosides as Anticancer Agents. National Am. Chem. Soc. Mtg., 1995.
17. Kirkovsky L, Mukherjee A, **Dalton JT**, and Miller DD. Chiral Non-Steroidal Antiandrogen Analogs of Hydroxyflutamide. National. Amer. Chem. Soc. Mtg., New Orleans, LA, 1996.
18. Mukherjee A, Kirkovsky L, Miller DD, and **Dalton JT**. In Vitro Pharmacologic Characterization of Nonsteroidal Affinity Ligands for the Androgen Receptor. Pharmaceutical Res., 13(9):S491, 1996.
19. Miller DD, Stourman N, Kirkovsky L, Zhu Z, and **Dalton JT**. Chiral Epoxides as Irreversible Probe for the Androgen Receptor. National Amer. Chem. Soc. Mtg., Las Vegas, NV, MEDI-222, 1997.
20. Kirkovsky L, Mukherjee A, **Dalton JT**, and Miller DD. 125I-Radioiodinated Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer. National Amer. Chem. Soc. Mtg., Las Vegas, NV, MEDI-155, 1997.
21. Mukherjee A, Kirkovsky L, Miller DD, and **Dalton JT**. Evaluation of Novel Radioiodinated Imaging Agents for Prostate Cancer: Androgen Receptor Binding and Pharmacokinetics in Rats. Pharmaceutical Res., 14(11):S77, 1997.
22. **Dalton JT**, Yao XT, and Shukla AJ. Controlled Release of Taxol from Biodegradable Injectable Gels. Pharmaceutical Res., 14(11):S284, 1997.
23. Mukherjee A, Kimura Y, Kirkovsky L, Miller DD, and **Dalton JT**. Alkylation of the Androgen Receptor with Nonsteroidal Affinity Ligands and Determination of their Functional Activity. Pharmaceutical Res., 14(11):S393, 1997.
24. Zhou D, Lu Y, Steiner MS, and **Dalton JT**. Sensitization of Human Tumor Cells to Cyclophosphamide using CYP2C9 Gene Transfer. Pharmaceutical Res., 14(11):S395, 1997.

25. Kidd RS, Straughn AB, Meyer MC, Goldstein JA, and **Dalton JT**. Pharmacokinetics of Chlorpheniramine, Phenytoin, Glipizide and Nifedipine in an Individual Homozygous for the CYP2C9*3 Allele. PharmSci, 1(1):S-34, 1998.
26. Yates CR, Kanangat S, Meduri U, and **Dalton JT**. Effect of Pro-Inflammatory Cytokines on Glucocorticoid Receptor Transcripts. PharmSci, 1(1):S-331, 1998.
27. **Dalton JT**, Zhang L, Marvel M, and Shukla AJ. Antitumor Efficacy of Taxol Released from Biodegradable Injectable Gels after Intratumoral Injection. PharmSci, 1(1):S-475, 1998.
28. **Dalton JT**, Mukherjee A, Zhou D, Young D, Golub AL, and Meyer MC. Pharmacokinetics of Aminolevulinic Acid (ALA) after Intravesical Administration in Dogs. PharmSci, 1(1):S-667, 1998.
29. Williams DH, **Dalton JT**, and Gollamudi R. Pharmacokinetics of a Potent Inhibitor of Platelet Activating Factor (PAF). PharmSci, 1(1):S-668, 1998.
30. Mukherjee A, Kirkovsky L, Marvel M, Miller DD, and **Dalton JT**. Development of Nonsteroidal Androgen Receptor Ligands for Imaging Prostate Tumors. PharmSci, 1(1):S-681, 1998.
31. Zhu Z, Bulgakov O, Scott SS, and **Dalton JT**. Recombinant Expression And Purification Of Human Androgen Receptor And Its Ligand Binding Domain In A Baculovirus System. PharmSci, 1(4): S-2606, 1999.
32. Yin D, Kirkovsky L, Stourman N, Miller DD, and **Dalton JT**. In Vitro Pharmacology And In Vivo Pharmacokinetics Of (R)-Para-Acetamido-Bicalutamide. PharmSci, 1(4):S-3185, 1999.
33. **Dalton JT**, Straughn AB, Meyer MC, Dickason D, and Grandolfi GP. A Human Pharmacokinetic Study Comparing RingCap^{TM} Tablets and Matrix Tablets. Controlled Release Society, 2000.
34. Sardar VM, Xu H, Virag T, Tigyi G, **Dalton JT**, and Miller DD. Lysophosphatidic Acid (LPA) Receptor Antagonists as Potential Cytotoxic Agents against Prostate Cancer Cell Lines. American Chemical Society, 2000.
35. Yin D, He Y, Xu H, Miller DD, and **Dalton JT**. Metabolism of (R)-Para-Acetamido Bicalutamide in Rats. PharmSci 2(4):2000.
36. Zhu Z and **Dalton JT**. Mass Spectroscopic Characterization of the Human Androgen Receptor Expressed in a Baculovirus System. PharmSci 2(4): 2000.
37. Yates CR, Vysokanov A, Mukherjee A, Ludden TM, Tolley E, Meduri GU, and **Dalton JT**. Time-Variant Increase in Methylprednisolone Clearance in Patients with Acute Respiratory Distress Syndrome: A Population Pharmacokinetic Study. PharmSci 2(4):2000.
38. Yates CR, Kearbey JD, Miller DD, and **Dalton JT**. P-Glycoprotein Transport of Glucocorticoids is Affected by A-Ring Conformation and B-Ring Substitution. PharmSci 2(4):2000.
39. Xu H, Sardar VM, Miller DD, and **Dalton JT**. Pharmacodynamics of Novel Lysophosphatidic Acid (LPA) Analogs in Prostate Cancer Cell Lines. PharmSci 2(4): 2000.
40. **Dalton JT**, Yin D, Perera MA, Gao W, Xu H, Kearbey JD, Chung K, and Miller DD. Preclinical Pharmacology and Pharmacokinetics of a Selective Androgen Receptor Modulator. International Society for Study of Xenobiotics. Drug Metabolism Reviews, 33(supplement 1): #222, 2001.
41. Gao W, Chung K, Kearbey JD, Miller DD, and **Dalton JT**. Pharmacologic Effects of Androxolutamide (GTx-007) on Male Rats of Varying Hormonal Status. The Endocrine Society, San Francisco, June 2002.
42. Kearbey JD, Chung K, Miller DD, and **Dalton JT**. Effect of Androxolutamide (GTx-007) on Bone Mineralization in Rats: A Pilot Study. The Endocrine Society, San Francisco, June 2002.
43. Perera MA, Yin D, Chung K, Miller DD, and **Dalton JT**. Pharmacokinetics of androxolutamide (GTx-007) in beagle dogs. The Endocrine Society, San Francisco, June 2002.
44. Chen J, Guan N, Chung K, Miller DD, and **Dalton JT**. Modulation of Hormonal Biomarkers and Target Organ Weights In Vivo by Selective Androgen Receptor Modulators (SARMs). PharmSci 4(4): 2002.
45. Gao W, Chung K, Miller DD, and **Dalton JT**. In Vitro Metabolism and In Vivo Tissue Selectivity of Andarine. PharmSci 4(4): 2002.
46. Kearbey JD, Wu D, Gao W, Chung K, Miller DD, and **Dalton JT**. Pharmacokinetics of a Nonsteroidal Selective Androgen Receptor Modulator in Rats. PharmSci 4(4): 2002.
47. Perera MA, Yin D, Chung K, Miller DD, and **Dalton JT**. Pharmacokinetics and Allometric Scaling of Andarine. PharmSci 4(4): 2002.
48. Xu H, Chung K, Hwang DJ, Miller DD, and **Dalton JT**. Pharmacodynamics of Electrophilic Androgen Receptor Ligands in Prostate Cancer Cell Lines. PharmSci 4(4): 2002.
49. Lin TS, **Dalton JT**, Wu D, Fischer B, Moran M, Shank R, Lucas D, Cunningham K, Colevas A, Grever MR, and Byrd JC. A phase I dose escalation study of apolizumab (Hu1D10) using a stepped up dosing schedule in patients

with chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL). Blood 100 (11): 3167 Part 1, 2002.

50. Chen J, Chung K, Hwang DJ, Miller DD, and **Dalton JT**. In Vitro Characterization of Novel Selective Androgen Receptor Modulators (SARMs). The Endocrine Society, Philadelphia, June 2003, Abstract #P1-87.
51. Wang L, Miller DD, and **Dalton JT**. Androgen Receptor Mediated Transcriptional Activation of SARMs is Enhanced by Nuclear Receptor Coactivators. The Endocrine Society, Philadelphia, June 2003, Abstract #P2-95.
52. Gao W, Kearbey JD, Chung K, Miller DD, and **Dalton JT**. Pharmacologic Effects of a Novel Selective Androgen Receptor Modulator (SARM), Flutamide and Finasteride in Intact Male Rats. The Endocrine Society, Philadelphia, June 2003, Abstract #P3-221.
53. Kim J, Hwang DJ, Miller DD, and **Dalton JT**. In vitro and In vivo Pharmacologic Activity of 4-Halo Substituted SARMs. The Endocrine Society, Philadelphia, June 2003, Abstract #P3-198.
54. Wu D, Miller DD, and **Dalton JT**. Electrospray LC/MS method using single-ion monitoring and a monolithic silica column for quantitation and preclinical pharmacokinetics of a novel selective androgen receptor modulator (SARM) in rats. American Society of Mass Spectrometry, Montreal, Canada, June 2003.
55. Wu Z, Bohl CE, Goldberger N, Miller DD, and **Dalton JT**. Peptide mapping of the human androgen receptor ligand-binding domain using mass spectrometry. American Society of Mass Spectrometry, Montreal, Canada, June 2003.
56. Fisher SJ, Miller DD, and **Dalton JT**. Preclinical Pharmacology of A-Ring Substituted Selective Androgen Receptor Modulators (SARMs). PharmSci 5 (4): W5248, 2003.
57. Gao W, Stuart LB, Yates CR, Miller DD, and **Dalton JT**. Regulation of Cytochrome P450s by Selective Androgen Receptor Modulators (SARMs) in Primary Culture of Human Hepatocytes.). PharmSci 5 (4): T3338, 2003.
58. Gao W, Veverka KA, Chung K, Miller DD, and **Dalton JT**. Species Difference in the Metabolism of Selective Androgen Receptor Modulators (SARMs). PharmSci 5 (4): T3336, 2003.
59. Gao W, Wu Z, Chung K, Miller DD, and **Dalton JT**. Phase I Metabolism Study of Selective Androgen Receptor Modulators (SARMs) with Human Liver Microsomes. PharmSci 5 (4): T3337, 2003.
60. Kearbey JD, Gao W, Miller DD, and **Dalton JT**. Selective androgen receptor modulators inhibit bone resorption in rats. PharmSci 5 (4): R6167, 2003.
61. Kim J, Hwang DJ, Nair VA, Miller DD, and **Dalton JT**. Pharmacokinetics of Halogen Substituted SARMs in Rats. PharmSci 5 (4): W5259, 2003.
62. Perera MA, Yin D, Chung K, Chan KK, Miller DD, and **Dalton JT**. Metabolism of a Novel Selective Androgen Receptor Modulator. PharmSci 5 (4): T3360, 2003.
63. Wu D, Gao W, Kearbey JD, Chung K, Miller DD, and **Dalton JT**. Pharmacokinetics of a selective androgen receptor modulator (SARM), S-1, in rats. PharmSci 5 (4): W5267, 2003.
64. Xu H, Hwang DJ, Miller DD, and **Dalton JT**. In Vitro and In Vivo Anticancer Activity of S-NTBA for Prostate Cancer. PharmSci 5 (4): T2378, 2003.
65. Hurh E, Gududuru V, Miller DD, and **Dalton JT**. 12-Phenylthiazolidine derivatives of lysophosphatidic acid as a new class of anticancer agents. Proceedings of American Association for Cancer Research, Abstract #2055, 2004.
66. Guan N, Hurh E, Korukonda R, Donkor IO, and **Dalton JT**. In vitro anti-leukemic activity of aldehyde calpain inhibitors. Proceedings of American Association for Cancer Research, Abstract #2092, 2004.
67. Xu H, Hwang DJ, Miller DD, and **Dalton JT**. Pharmacodynamics of electrophilic androgen receptor ligands in prostate cancer cell lines. Proceedings of American Association for Cancer Research, Abstract #5397, 2004.
68. Bohl CE, Chang C, Mohler ML, Swaan PW, Miller DD, and **Dalton JT**. A Ligand-Based Approach to Identify Quantitative Structure Activity Relationships for the Androgen Receptor. The Endocrine Society, New Orleans, Abstract# P2-156, June 2004.
69. Chen J, Hwang DJ, Miller DD, and **Dalton JT**. A Selective Androgen Receptor Modulator (SARM) for Male Contraception. The Endocrine Society, New Orleans, Abstract # P2-103, June 2004.
70. Gao W, Reiser PJ, Kearbey JD, Phelps MA, Coss CC, Miller DD, and **Dalton JT**. Effects of a Novel Selective Androgen Receptor Modulator (SARM) on Skeletal Muscle Mass and Strength in Castrated Male Rats. The Endocrine Society, New Orleans, Abstract # P2-120, June 2004.

71. Chen J, Hwang DJ, Mustafa S, Miller DD, and **Dalton JT**. In Vitro And In Vivo Structure-activity Relationships (sars) Of Novel Androgen Receptor (AR) Ligands With Multiple Substitutions On The B-ring. The AAPS Journal, Vol. 6, No. 4, Abstract #T3354, November 2004.
72. Wu D, Wu Z, Nair V, Miller DD, and **Dalton JT**. Urinary Metabolites Of S-1, A Novel Selective Androgen Receptor Modulator (SARM), In Rats. The AAPS Journal, Vol. 6, No. 4, Abstract #W5300, November 2004.
73. Chen J, Xiao J, Chung K, Miller DD, and **Dalton JT**. Preclinical Pharmacology, Pharmacokinetics, And Metabolism Of A Novel Selective Androgen Receptor Modulator (SARM) In Male Rats. The AAPS Journal, Vol. 6, No. 4, Abstract #W5299, November 2004.
74. Johnston J, **Dalton JT**, and Swaan PW. Guggulsterone Acts As A Specific Mrp1 Inhibitor. The AAPS Journal, Vol. 6, No. 4, Abstract #T2243, November 2004.
75. Fisher SJ, Hong SS, Miller DD, and **Dalton JT**. Preclinical Pharmacology And Pharmacokinetics Of A Novel A-ring Substituted Selective Androgen Receptor Modulator (SARM) In Rats. The AAPS Journal, Vol. 6, No. 4, Abstract #T2256, November 2004.
76. Bohl CE, Chang C, Mohler M, Miller DD, Swaan PW, and **Dalton JT**. A Ligand-based Approach To Identify Quantitative Structure Activity Relationships For The Androgen Receptor. The AAPS Journal, Vol. 6, No. 4, Abstract #W4111, November 2004.
77. Kim J, Hwang DJ, Miller DD, and **Dalton JT**. Effect Of 4-cyano And 4-nitro Substitution On The Pharmacologic Activity And Pharmacokinetics Of Selective Androgen Receptor Modulators. The AAPS Journal, Vol. 6, No. 4, Abstract #W4118, November 2004.
78. Hurh E, Taxter A, Gududuru V, Miller DD, and **Dalton JT**. Enhancement Of Bicalutamide Activity By Lysophospholipid Analogs In Prostate Cancer Cells. The AAPS Journal, Vol. 6, No. 4, Abstract #W4078, November 2004.
79. Phelps M, Foraker A, Gao W, **Dalton JT**, and Swaan PW. Physicochemical And Spectral Characterization Of A Novel Rhodamine-riboflavin Conjugate. The AAPS Journal, Vol. 6, No. 4, Abstract #T2292, November 2004.
80. Hwang DJ, Kim J, **Dalton JT**, Miller DD. Synthesis and androgen receptor affinity of several linkages of 1,3-disubstituted-2-hydroxy-2-methylpropionamide selective androgen receptor modulators (SARMs). Abstracts of Papers of the American Chemical Society, 229: U139-U139 173-MEDI Part 2, March 13, 2005.
81. Hwang DJ, Chen JY, Kim J, **Dalton JT**, Miller DD. Synthesis and biological testing of (2S)-multi-halogenated B-ring 2-hydroxy-2-methylpropionamide selective androgen receptor modulators (SARMs): Probing the B-ring pocket. Abstracts of Papers of the American Chemical Society, 229: U140-U140 176-MEDI Part 2, March 13, 2005.
82. Hwang DJ, Chen JY, Xu HP, Mustafa SM, **Dalton JT**, Miller DD. Synthesis of isothiocyanate derivatives of irreversible selective androgen receptor modulators (SARMs) and biological testing in prostate cancer cell lines. Abstracts of Papers of the American Chemical Society, 229: U140-U140 177-MEDI Part 2, March 13, 2005.
83. Gududuru V, Hurh E, **Dalton JT**, and Miller DD. Polyamine conjugates of serine, 4-thiazolidinone and thiazolidine-4-carboxylic acid: Synthesis and growth inhibitory effects on human prostate cancer cell lines. Abstracts of Papers of the American Chemical Society, 229: U199-U199 500-MEDI Part 2 March 13, 2005.
84. Gududuru V, Hurh E, **Dalton JT**, Miller DD. Polyamine conjugates of serine, 4-thiazolidinone and thiazolidine-4-carboxylic acid: Synthesis and growth inhibitory effects on human prostate cancer cell lines. Abstracts of Papers of the American Chemical Society, 229: U205-U205 500-MEDI Part 2, March 13, 2005.
85. Hurh E, Gududuru V, Miller DD, and **Dalton JT**. Effect of lysophosphatidic acid on lysophospholipid analog-induced cytotoxicity in prostate cancer cells. Proceedings of the American Association for Cancer Research, Abstract #642, April 2005.
86. Bohl CE, Gao W, Miller DD, and **Dalton JT**. The crystal structure of the androgen receptor W741L mutant ligand binding domain bound to bicalutamide. Proceedings of the American Association for Cancer Research, Abstract #2533, April 2005.
87. Guan N, Korukonda R, Donkor IO, and **Dalton JT**. Apoptosis induced by calpain inhibitors in leukemia cells and HeLa cells. Proceedings of the American Association for Cancer Research, Abstract #4984, April 2005.
88. Yang J, Hurh E, Hwang DJ, Xu H, Miller DD, and **Dalton JT**. G2-M block, apoptosis, and cytotoxicity are potently induced by novel bis-indoles in prostate cancer cells. Proceedings of the American Association for Cancer Research, Abstract #5898, April 2005.

89. Bisson WH, Cheltsov A, Chen JY, **Dalton JT**, Zhang XK, Abagyan R In silico virtual ligand screening as a powerful tool to discover side effects of marketed and novel drugs. Abstracts of Papers of the American Chemical Society, 230: U2746-U2747 432-MEDI, August 28, 2005.
90. Hurh E, Wu Z, Wu D, Gududuru V, Miller DD, **Dalton JT**. Pharmacokinetics and In Vitro Hepatic Metabolism of 2-Arylthiazolidine Analogs. The AAPS Journal, Vol. 7 (S2):W5271, 2005.
91. Yang J, Hwang DJ, Wu Z, Hurh E, Guan N, Xu H, Miller DD, **Dalton JT**. Pharmacokinetics, metabolism and toxicity of a novel anticancer agent in mice. The AAPS Journal, Vol. 7(S2):T3322, 2005.
92. Chen J, Hwang DJ, Chung K, Nelson R, Miller DD, **Dalton JT**. In Vitro and In Vivo Characterization of a Selective Androgen Receptor Modulators (SARM). The AAPS Journal, Vol. 7(S2):T3259, 2005.
93. Wu D, Byrd J, Lin T, Fischer B, Grever M, **Dalton JT**. Population Pharmacokinetics of flavopiridol in CLL/SLL patients. The AAPS Journal, Vol. 7(S2):W5059, 2005.
94. Kim J, Hwang DJ, Rakov I, Miller DD, and **Dalton JT**. Structure-Activity Relationships for Modification of the Linkage Group and B-Ring of Selective Androgen Receptor Modulators. The AAPS Journal, Vol. 7(S2):T2117, 2005.
95. Hwang DJ, Yang J, Mohler ML, **Dalton JT**, Miller DD.Synthesis and testing of both reversible and irreversible selective androgen receptor modulators (SARMs) for prostate cancer . Abstracts of Papers of the American Chemical Society, 231: 274-MEDI, March 26 2006.
96. Kearbey JD, Parke DN, Narayanan R, Okolicany J, Miller DD, and **Dalton JT**. Preclinical Pharmacology of a Novel Osteoanabolic Tissue Selective Androgen Receptor Modulator. The Endocrine Society, Boston, Abstract # P3-64, June 2006.
97. Goldberger NE, Wu Z, and **Dalton JT**. Using Mass Spectroscopy To Study Ligand-Specific Androgen Receptor (AR) Conformations and Complexes. The Endocrine Society, Boston, Abstract # P3-461, June 2006
98. Gao W, Coss CC, and **Dalton JT**. Tissue-Specific Regulation of Transcription Repressor Slug Expression by Androgen Receptor Ligand (DHT). The Endocrine Society, Boston, Abstract # P3-462, June 2006
99. Narayanan R, Bohl CE, Kearbey JD, Coss CC, Miller DD, and **Dalton JT**. Molecular Mechanism for the Tissue Selectivity of a Novel Non-Steroidal Selective Androgen Receptor Modulator: Genome-Wide Mapping of Androgen Receptor Binding Sites. The Endocrine Society, Boston, Abstract # OR49-1, June 2006.
100. Byrd JC, Lin TS, **Dalton JT**, Phelps M, Fischer B, Moran M, Blum K, Rovin B, Colevas AD, Grever MR. Pharmacologically derived schedule of flavopiridol has significant efficacy in refractory, genetically high risk chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology, 24 (18): 341S-341S Part 1 Suppl. S, American Society of Clinical Oncology, June 20, 2006.
101. Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, **Dalton JT**, Lucas D, Colevas AD, Grever MR, Marcucci G, Byrd JC. Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics. Journal of Clinical Oncology, 24 (18): 353S-353S Part 1 Suppl. S, American Society of Clinical Oncology, June 20, 2006
102. Press B, Snyder L, Reust M, **Dalton JT**, Yuan DZ, Veverka KA. In vitro metabolic profile of novel nonsteroidal selective androgen receptor modulators. Drug Metabolisms Reviews, 38: 92-93 146 Suppl. 2, 2006. International Society for the Study of Xenobiotics, Puerto Rico. October 2006.
103. Liu Q, Zhao XB, Frissora F, Ma Y, Santhanam R, Perrotti D, Chen CS, **Dalton JT**, Byrd JC, Muthusamy N. FTY720 (2-amino-2-[2-(4-octylphenyl) ethyl] propane 1, 3-diol hydrochloride), mediates cytotoxicity through caspase independent and protein phosphatase 2A dependent mechanisms in chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 108 (11): 594A-594A 2095 Part 1, American Society of Hematology, November 16, 2006.
104. Lin TS, Phelps M, **Dalton JT**, Fischer B, Blum KA, Moran ME, McEldowney MB, Broering S, Colevas D, Byrd JC, Grever MR. Flavopiridol can be safely dose escalated in relapsed CLL patients: Achievement of target C-max results in improved clinical activity. Blood 108 (11): 805A-806A 2845 Part 1, American Society of Hematology, November 16, 2006.
105. Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, **Dalton JT**, Lucas D, Huynh LN, Liu S, Grever MR, Colevas AD, Marcucci G, Byrd JC. Updated results of a phase I study of flavopiridol in acute leukemias using a novel, pharmacolkinetically derived schedule: Clinical activity including hyperacute tumor lysis syndrome (TLS), pharmacokinetics (PIC), and pharmacodynamics (PD). Blood 108 (11): 224B-224B 4578 Part 2, American Society of Hematology, November 16, 2006.

106. Wulff BC, Tober KL, Phelps MA, Ducan FJ, Vanbuskirk AM, Kusewitt DF, **Dalton JT**, and Oberyszyn TM. Effects of therapeutic immunosuppressants on progression of UVB induced skin tumors. Proceedings of the American Association for Cancer Research, Los Angeles, Abstract #228, April 15, 2007.
107. Ramaswamy B, Lai JP, Phelps MA, **Dalton JT**, Arbogast D, Wilkins D, Colevas D, Byrd JC, Grever MR, and Shah M. A phase I study of flavopiridol using an alternative schedule of 30-min loading dose followed by a 4-hour IV infusion in patients (pts) with advanced solid tumors. Proceedings of the American Association for Cancer Research, Los Angeles, Abstract #925, April 15, 2007.
108. Phelps MA, Wu D, Dai Z, Hurh E, Johnson AJ, Farley KL, Schaaf LJ, Sadee W, Lin TS, Byrd JC, Grever MR, and **Dalton JT**. Population pharmacokinetics, pharmacodynamics and pharmacogenomics of flavopiridol with a clinically active dosing schedule in patients with chronic lymphocytic leukemia Proceedings of the American Association for Cancer Research, Los Angeles, Abstract #928, April 15, 2007.
109. Zhao Wang, Yan Lu, Veeresa Gududuru, Blazej Zbytek, Michal A. Zmijewski, Andrzej T. Slominski, James T. Dalton, Duane D. Miller, Wei Li, Synthesis and SAR Studies of Novel thiazolidine analogs for melanoma, 2007, AACR annual meeting, Los Angeles, Abstract #3963, April 16, 2007.
110. Wang Z, Lu Y, Gududuru V, Zbytek B, Zmijewski MA, Slominski AT, **Dalton JT**, Miller DD, and Li W. Synthesis and SAR Studies of novel thiazolidine analogs for melanoma Proceedings of the American Association for Cancer Research, Los Angeles, Abstract #3963, April 17, 2007.
111. Eswaraka J., Barrett C., Kearbey J., Coss C., Hong S.S., Miller D., Dalton J. Discovery and Preclinical Characterization of GTx-103: A Novel SERM useful for alleviating hot flushes. Proceedings of the European Molecular Biology Association conference on Nuclear Receptors: Structure and Function in Health and Disease, Gardone Riviera, Lake Garda, Italy, #PII.53, page 57, May 2-5, 2007.
112. Narayanan R, Coss CC, Yepuru MM, Miller DD and **Dalton JT**. Steroidal Androgens and Nonsteroidal, Tissue Selective Androgen Receptor Modulators (SARM) Regulate Androgen Receptor Function Through Distinct Genomic and Non-Genomic Signaling Pathways. The Endocrine Society, Toronto, Abstract # P1-595, June 2007.
113. Yepuru MM, Coss CC, Barrett CM, Eswaraka J, Costello T, Miller DD, Narayanan R and **Dalton JT**. An Estrogen Receptor-b Specific Selective Estrogen Receptor Modulator (SERM) Inhibits the Growth of Prostate Cancer Cells and Stromal-Epithelial Tumor Xenograft. The Endocrine Society, Toronto, Abstract # OR6-3, June 2007.
114. Blum W, Klisovic RB, Johnson A, Kefauver C, Phelps M, Lucas D, Huynh L, Liu S, **Dalton JT**, Grever MR, Marcucci G, Byrd JC. Final results of a dose escalation study of flavopiridol in acute leukemias using a novel-treatment schedule. Blood, 110 (11): 272A, Abstract: 890, November 16, 2007.
115. Heerema NA, Byrd JC, Andritsos LA), Lozanski G, Blum K, Fischer B, Jones JA, Moran ME, Groering S, Schaaf LJ, Mahoney LS, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps MA, **Dalton JT**, Grever MR, Lin TS. Clinical activity of flavopiridol in relapsed and refractory chronic lymphocytic leukemia (CLL) with high-risk cytogenetic abnormalities: Updated data on 89 patients (Pts).Blood, 110 (11); 914A, Abstract: 3107, November 16, 2007.
116. Raghow S, Jolette J, Smith SY, Tumer CH, Farrell D, **Dalton JT**, Veverka KA. Toremifene preserves bone architecture and strength in aged orchiectomized rat. Journal of Bone and Mineral Research, 22: S207, Suppl. 1, Abstract: M406, September 2007.
117. Chen J, Wang Z, Lu Y, **Dalton JT**, and Miller DD. Synthesis and Antiproliferative Activity of Metabolically Stable Thiazolidine Analogs for Melanoma. Proceedings of American Association for Cancer Research, San Diego, CA, Abstract #1282, April 2008.
118. Ahn S, Duke CB, Hwang DJ, Miller DD, and **Dalton JT**. In Vitro and In Vivo Studies of a Novel Indole with Potent Antimitotic Activity in Prostate Cancer and Drug-Resistant Tumors. Proceedings of American Association for Cancer Research, San Diego, CA, Abstract #1417, April 2008.
119. Liu Q, Alinari L, Chen CS, **Dalton JT**, Byrd J, Baiocchi R, and Muthusamy N. FTY720-Mediated Toxicity in Mantle Cell Lymphoma is Associated with Down-Modulation of Cyclin D1 and Akt. Proceedings of American Association for Cancer Research, San Diego, CA, Abstract #2826, April 2008.
120. S Raghow, RA Morton, M Hancock, MS Steiner and JT Dalton. Estrogen Receptor Beta (ERβ) Expression is Lower in Biopsy Samples from Patients with Prostate Cancer than Patients with High Grade Prostatic Intraepithelial Neoplasia (HGPIN). Society for Basic Urological Research (SBUR), 2008.
121. Heerema NA, Lin TS, Fischer B, Lozanski G, Blum KA, Andritsos LA, Jones JA, Flynn JM, Moran ME, Mitchell SM, Schaaf LJ, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps M, **Dalton JT**, Grever MR, and Byrd

JC. Chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetics respond to treatment with flavopiridol: Study of 120 patients (pts) with relapsed, genetically high risk CLL 40th Biennial American Cytogenetic Conference, Monterey, CA. Cytogenetics and Genome Research, 121 (1): Abstract: # 14, 2008.

122. Raghow S, **Dalton JT**, Doyle N, Jolette J, Smith SY, Veverka KA, Narayanan R. Toremifene Inhibits Osteoclast Activity in vitro and Prevents Orchiectomy-induced Bone Resorption in Male Rats. American Society for Bone and Mineral Research, Montreal, CA, September 13, 2008. Journal of Bone and Mineral Research, 23 (suppl): S204-S205, 2008.
123. Narayanan R, Yepuru M, Eswaraka J, Barrett CM, Wu Z, Miller DD, **Dalton JT**. Preclinical Evidence for the Management of Metabolic Diseases by GTx-828, an Estrogen Receptor β Selective Ligand. Abstract #P1-36, Annual Meeting of the Endocrine Society, Washington, DC, June 10, 2009.
124. Morton, Jr. RA, Barnette KG, Hancock ML, Rodriguez D, **Dalton JT**, Steiner MS. The Use of a Selective Androgen Receptor Modulator To Improve Lean Body Mass and Muscle Performance in Patients with Cancer Cachexia. Abstract #S21-1, Annual Meeting of the Endocrine Society, Washington, DC, June 11, 2009.
125. Wang Z, Lu Y, Chen J, Loveless VS, **Dalton JT**, Miller DD and Li W. In vitro and in vivo evaluation of substituted methoxylbenzoyl-aryl-thiazole derivatives as potent anticancer agents for advanced melanoma. Annual Meeting of the American Association for Cancer Research, Denver, CO, April 17-22, 2009.
126. Li, CM Lu Y, Narayanan R, Miller DD and **Dalton JT**. 2-Arylthazolidine-4-Carboxylic Acid Amides (ATCAA) target dual pathways: Effects on the 5'-AMP-Activated Protein Kinase (AMPK) and Akt pathways, abstract 4416, Annual Meeting of the American Association for Cancer Research, Denver, CO, April 17-22, 2009.
127. Ahn S, Duke CB, Hwang DJ, Miller DD, and **Dalton JT**. In vitro and in vivo studies of novel indoles that exert antimitotic activity in prostate cancer and multidrug-resistant tumor cells with less neurotoxicity. Annual Meeting of the American Association for Cancer Research, Abstract #3326, Denver, CO, April 21, (2009).
128. Kim J, Peraire C, Froelich J, Sola J, Barnette KG, **Dalton JT**, Veverka KA. Nonclinical and clinical assessment of pharmacokinetic drug-drug interactions with toremifene. 16th North American Regional ISSX Meeting, Drug Metabolism Reviews 41 (suppl 3):80-81, Abstract #164, 2009, Baltimore, MD, October 2009.
129. Alinari L, Liu Q, Chen CS, Yan FT, **Dalton JT**, Lapalombella R, Zhang XL, Lin T, Byrd JC, Baiocchi RA, Muthusamy N. FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma. 51st Annual Meeting of the American-Society-of-Hematology, Blood 114 (22): 1436, 2009, New Orleans, LA, December 05-08, 2009.
130. Giddabasappa A, Bauler M, **Dalton JT**, Eswaraka JR. GTx-878, an Estrogen Receptor b agonist, Inhibits Retinal Neovascularization in the Mouse Model of Oxygen Induced Retinopathy. Program #: 2793/D831, Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, May 04, 2010.
131. Eswaraka JR, Giddabasappa A, **Dalton JT**, Bauler M, Barrett C. GTx-822, a Selective Estrogen Receptor β (ERβ) Ligand Protects Mitochondria in ARPE-19 Cells Through Genomic and Non-Genomic Pathways. Program # 6161/D673, Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL. May 2010.
132. Thevis M, Gerace, Thomas A, Beuck S, Geyer H, Schlorer N, Kearbey JD, **Dalton JT**, Schanzer W. Characterization of in vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23 and in vivo comparison to post-administration canine urine specimens. 28th Manfred Donike Cologne Workshop on Dope Analysis, Cologne, Germany, March 2010.
133. Narayanan R, Jiang J, Gusev YD, Jones A, Miller DD, Schmittgen TD, **Dalton JT**. DHT Promotes Muscle and Prostate Growth through a Positive Feedback Loop Involving Androgen Receptor, microRNA and Corepressors. Annual meeting of The Endocrine Society, Endocrine Reviews 31 (3, suppl 1): S2, San Diego, CA, June 2010.
134. Duke CB, Jones A, Bohl C, **Dalton JT**, Miller DD. Synthesis and biological studies of androgen receptor ligands: Towards mutation-resistant nonsteroidal antagonism. Abstracts of the American Chemical Society, Poster #355-MEDI, Boston, MA, August 22, 2010.
135. Lu Y, Li CM, Wang Z, Chen JJ, **Dalton JT**, Li W, Miller DD. Synthesis, biological evaluation and structure-activity relationships of 4-substituted methoxybenzoyl aryl thiazole (SMART) as anticancer agents Source: Abstracts of the American Chemical Society, Poster #340-MEDI, Boston, MA, August 22.
136. Kearbey JD, Parke D, **Dalton JT**. Improved Bone Quality and Suppression of Testosterone Levels by a Novel Selective Estrogen Receptor α Agonist. Society for Basic Urological Research, Atlanta, GA November 11-14, 2010.

137. Narayanan R, Jones A, Varela A, **Dalton JT**, Veverka KA. Anti-Prostate Effects of a Selective Estrogen Receptor-α Agonist, GTx-758, In Vitro and in Aged Male Cynomolgus Monkeys. November 11-14, 2010, Society for Basic Urological Research, Atlanta, GA.
138. Veverka KA, Giddabasappa A, Jones A, Bauler M, Eswaraka J, Narayanan R, **Dalton JT**. Oral Administration of GTx-758 Reduces Serum Testosterone but does not Increase Whole Blood Platelet Aggregation in Mature Male Cynomolgus Monkeys. Society for Basic Urological Research, Atlanta, GA November 11-14, 2010.
139. Ahn S, Duke III CB, Barrett CM, Hwang DJ, Li CM, Miller DD, **Dalton JT**. Potent antitumor activity and pharmacokinetics of a novel microtubule polymerization inhibitor in xenograft models of multidrug-resistant tumors. Society for Basic Urological Research, Atlanta, GA November 11-14, 2010.
140. Ahn S, Duke III CB, Hwang DJ, Li CM, Miller DD, **Dalton JT**. In vitro and in vivo studies of novel indoles that exert antimitotic activity in prostate cancer and multidrug-resistant tumor cells with less neurotoxicity, International Pharmaceutical Federation's Pharmaceutical Sciences World Congress / American Association of Pharmaceutical Scientists Annual Meeting, Abstract #W5006, New Orleans, LA, November 17, 2010.
141. Ahn T, Kearbey JD, Parke D, **Dalton JT**, Gosnell M. Microemulsion based oral drug delivery of PRD-0936, International Pharmaceutical Federation's Pharmaceutical Sciences World Congress / American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, LA, November 13, 2010.
142. Jones A, Narayanan R, Hwang DJ, Miller DD, **Dalton JT**. The Effects of a Novel SARM on Glucocorticoid-Induced and Hypogonadism-Induced Muscle Atrophy. International Pharmaceutical Federation's Pharmaceutical Sciences World Congress / American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, LA, November 13, 2010.
143. Kim J, Simpson E, Snyder L, **Dalton JT**, Veverka KA. Excretion Mass Balance of Radioactivity Following a Single Oral Dose of [^{14}C]PRD-0936 to Intact and Bile Duct Cannulated Male and Intact Female Rats. International Pharmaceutical Federation's Pharmaceutical Sciences World Congress / American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, LA, November 13, 2010.
144. Veverka KA, Kim J and **Dalton JT**. CYP2D6 Status Does Not Significantly Affect Toremifene Metabolism, Miami Breast Cancer Conference, Miami, FL, February 2011.
145. Jones A, Getzenberg R, **Dalton JT**, and Veverka KA. Oral Administration of GTx-758, a Selective ERa Agonist, Induces Chemical Castration but Not Gynecomastia in Male Monkeys. Annual meeting of the American Urological Association, Washington, DC May 17, 2011.
146. Jones A, Samadfam R, **Dalton JT**, Veverka KA. GTx-758 Reduces Serum Testosterone without Increasing Fat Mass in Mature Male Cynomolgus Monkeys. Annual meeting of The Endocrine Society, Poster # P2-26, Boston, MA, June 5, 2011.
147. Lu Y, Li CM, Wang Z, Wang J, Chen J, Li W, **Dalton JT**, and Miller DD. Synthesis and SAR Studies of Colchicine Binding Site Tubulin Inhibitors as Potent and Orally Bioavailable Anticancer Agents. American Chemical Society, Poster # 14735, Denver, CO, August 29, 2011.
148. Ahn S, Li CM, Barrett CM, Chen JJ, Li W, Lu Y, Miller DD, **Dalton JT**. GTx-230: an orally available novel tubulin inhibitor that disrupts tumor vasculature and displays single-agent antitumor efficacy in multidrug-resistant prostate cancer with less neurotoxicity. American Association for Cancer Research, Poster #2788, Chicago, IL, April 02, 2012.
149. Narayanan R, Yepuru M, Wu Z, Miller DD and **Dalton JT**. Impact of Selective Estrogen Receptor β Ligands on Obesity. S156, pp45, Experimental Biology, San Diego, CA, April 21-25, 2012.
150. Dodson ST, Johnston MA, Hancock ML, Steiner MS and **Dalton JT**. Effect of Enobosarm on Physical Function in Cancer Patients with < or ≥5% Weight Loss in a Phase IIB Trial. Multinational Association of Supportive Care in Cancer (MASCC). New York, NY. June 30, 2012.
151. Dodson ST, Dobs A, Johnston MA, Hancock ML, Morton RA, Steiner MS and **Dalton JT**. Prevalence and Impact of Hypogonadism in Cancer Patients with Muscle Wasting in a Phase IIB Enobosarm Trial. Multinational Association of Supportive Care in Cancer (MASCC). New York, NY. June 30, 2012.
152. **Dalton JT**, Johnson MA and Steiner MS. Enobosarm, a Selective Androgen Receptor Modulator, Demonstrates a Clinically Relevant Improvement in Physical Function in Non-Small Cell Lung Cancer (NSCLC) in Patients with Muscle Wasting. Seventh International Academy on Nutrition and Aging. Albuquerque, NM. July 12, 2012.

153. Steiner MS, Johnston MA, Hancock ML and **Dalton JT**. Effect of Enobosarm on Physical Function in Cancer Patients with < or ≥5 % Weight Loss in a Phase IIb Trial. Cancer Cachexia Conference, Boston, MA. September 21-23, 2012.
154. Steiner MS, Johnston MA, Hancock ML and **Dalton JT**. Prevalence and Impact of Hypogonadism in Cancer Patients with Muscle Wasting in a Phase IIb Enobosarm Trial. Cancer Cachexia Conference, Boston, MA. September 21-23, 2012.
155. Steiner MS, Taylor RP, Getzenberg RH, Johnston MA, Hancock ML and **Dalton JT**. The ERα Agonist, GTx-758, has a Distinct Mechanism of Action and Side Effect Profile Than DES. Western Regional Meeting of American Urological Association. Waikoloa, Hawaii. October 7-12, 2012.
156. **Dalton JT**, Coss CC, Johnston MA, Hancock ML, Taylor RP and Steiner MS. GTx-758 Is A Potent Oral ERα Agonist That Increases Sex Hormone Binding Globulin and Decreases Serum Free Testosterone In Men With Advanced Prostate Cancer. Western Regional Meeting of American Urological Association. Waikoloa, Hawaii. October 7-12, 2012.
157. Steiner MS, Taylor RP, Getzenberg RH, Johnston MA, Hancock ML, **Dalton JT**. GTx-758, An Oral ERα Agonist, Increases Sex Hormone Binding Globulin, Reduces Free T and Decreases PSA in Patients with Castration Resistant Prostate Cancer. Western Regional Meeting of American Urological Association. Waikoloa, Hawaii. October 7-12, 2012.
158. Getzenberg RH, Coss CC, Si X, Hancock ML, **Dalton JT**, Steiner MS. The ERα agonist GTx-758, further reduces free testosterone compared with LHRH agonist-based ADT providing for a more complete castration in men with advanced prostate cancer. International Prostate Cancer Update Meeting, Vail, CO, January 24, 2013.
159. Narayanan R, Yepuru M, Wu Z, Barrett C, Kim J, Penning TM, Steiner MS, Miller DD and **Dalton JT**. Aldo-Keto Reductase (AKR) 1C3 is an Androgen Receptor Coactivator. P100, American Society for Clinical Oncology, Genitourinary Symposium, Orlando, FL, February 14-16, 2013.
160. Yu EY, Gittelman M, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gayliss F, Bailen J, Getzenberg RH, Coss CC, Hancock ML, **Dalton JT**, Steiner MS. GTX-758, an ERα Agonist, Reduces Serum Free Testosterone and Serum PSA in Men with Advanced Prostate Cancer. American Society for Clinical Oncology, Genitourinary Symposium, Orlando, FL, February 14-16, 2013.
161. Yu EY, Gittelman M, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gayliss F, Bailen J, Getzenberg RH, Coss CC, Hancock ML, **Dalton JT**, Steiner MS. Serum IGF-1 levels are decreased in men with advanced prostate cancer treated with the ERα agonist, GTx-758. American Society for Clinical Oncology, Genitourinary Symposium, Orlando, FL, February 14-16, 2013.
162. Yu EY, Gittelman M, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Getzenberg RH, Coss CC, Hancock ML, **Dalton JT**, Steiner MS. The ERα agonist, GTx-758, decreases bone turnover markers in men with advanced prostate cancer. American Society for Clinical Oncology, Genitourinary Symposium, Orlando, FL, February 14-16, 2013.
163. Yu EY, Gittelman M, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Getzenberg RH, Coss CC, Hancock ML, **Dalton JT**, Steiner MS. Advanced prostate cancer patients treated with GTx-758 have a significantly lower rate of hot flashes. American Society for Clinical Oncology, Genitourinary Symposium, Orlando, FL, February 14-16, 2013.
164. Ahn S, Steiner MS, Narayanan R and **Dalton JT**. Nonsteroidal, Tissue Selective Androgen Receptor Modulators (SARMs) as targeted Therapy for the Treatment of Breast Cancer. P99, 2nd Congress on Steroid Research, Chicago, IL, March 10-12, 2013.
165. Narayanan R, Yepuru M, Wu Z, Steiner MS, Miller, DD and Dalton, JT. AKR1C3 is an Androgen Receptor Coactivator. P2, 2nd Congress on Steroid Research, Chicago, IL, March 10-12, 2013.
166. Getzenberg RH, Coss CC, Hancock ML, **Dalton JT**, Steiner MS. GTx-758, an ERα agonist, reduces serum free testosterone lower than can be achieved by leuprolide with a significantly lower rate of hot flashes in men with advanced prostate cancer. European Association of Urology, Milan, Italy, March 16, 2013.
167. Getzenberg RH, Hancock M, **Dalton JT**, Steiner MS. Advanced prostate cancer patients treated with GTx-758 have a significantly lower rate of hot flashes than those treated with Lupron. European Association of Urology, Milan, Italy, March 16, 2013.
168. Park K, **Dalton JT**, Narayanan R, Hancock M, Bostwick D, Steiner MS and Rubin M. ERG Gene Translocation Predicts Progression of High Grade Prostatic Intraepithelial Neoplasia to Prostate Cancer. American Urological Association, San Diego, CA, May 8, 2013.

169. Gunselman J, Gor R, Cahn D, Diorio G, Belkoff L, Getzenberg R, Hancock M, **Dalton JT** and Steiner MS. The ERα Agonist, GTx-758, Results in a Significantly Lower Rate of Hot Flashes and Bone Turnover in Comparison to Leuprolide in Men with Advanced Prostate Cancer. American Urological Assoc, San Diego, CA, May 7, 2013.
170. Matsumoto AM, Getzenberg RH, Coss CC, Hancock M, Si X, **Dalton JT**, Steiner MS. Confirmation of the free hormone hypothesis in prostate cancer: Decreases in PSA correlate with free testosterone rather than total testosterone in men with advanced prostate cancer treated with GTx-758. American Society of Clinical Oncology, Chicago, IL, May 31, 2013.
171. Coss CC, Getzenberg RH, Steiner MS and **Dalton JT**. GTx-758, ERa Agonist, Reduces Both Serum Free Testosterone(T) and Serum PSA in Men with Advanced and Castrate Resistant Prostate Cancer. The Endocrine Society, San Francisco, CA, June 15, 2013.
172. Narayanan R and **Dalton JT**. Tissue Selective Nonsteroidal Androgen Receptor Modulator (SARM), Enobosarm, and Steroidal Androgens Regulate Androgen Receptor Function through Distinct Cofactor Interactions and Recruitment. The Endocrine Society, San Francisco, CA, June 17, 2013.
173. Pedram AA, Razandi M, Korach KS, Narayanan R, **Dalton JT** and Levin ER. An ERß Selective Agonist Inhibits Angiotensin-Induced Cardiovascular Pathology. The Endocrine Society, San Francisco, CA, June 15, 2013.
174. Narayanan, R. and **Dalton JT**. Tissue Selective Nonsteroidal Androgen Receptor Modulator (SARM), Enobosarm, and Steroidal Androgens Regulate Androgen Receptor Function through Distinct Cofactor Interactions and Recruitment. Endocrine Society Annual Meeting, San Francisco, CA, June 15-18, 2013.
175. Narayanan, R., Ahn, S., Steiner, MS. and **Dalton JT**. Nonsteroidal, Tissue Selective Androgen Receptor Modulator (SARM) as Targeted Therapy for the Treatment of Androgen Receptor-Positive Breast Cancer. Gordon Research Conference, Hormone-Dependent Cancer, July 28-Aug 2, 2013.
176. Getzenberg RH, Matsumoto AM, Coss CC, Hancock M, Si X, **Dalton JT**, Steiner MS. Confirmation of the Free Hormone Hypothesis: Decreases in PSA Correlate with Free Testosterone Rather than Total Testosterone in Men with Advanced Prostate Cancer Treated with GTx-758. Mid Atlantic Regional Meeting of the American Urological Association, White Sulphur Springs, WV, October 24 – 27, 2013.
177. Gor R, Cahn DB, Gunselman J, Diorio G, Belkoff L, Getzenberg RH, Hancock ML, **Dalton JT**, Steiner ML. Androgen Deprivation Therapy with GTx-758 Significantly Decreases Markers for Bone Turnover Compared to Leuprolide in Men with Advanced Prostate Cancer. Mid Atlantic Regional Meeting of the American Urological Association, White Sulphur Springs, WV, October 24 – 27, 2013.
178. Getzenberg RH, Matsumoto AM, Coss CC, Hancock M, Si X, **Dalton JT**, Steiner MS. Confirmation of the Free Hormone Hypothesis: Decreases in PSA Correlate with Free Testosterone Rather than Total Testosterone in Men with Advanced Prostate Cancer Treated with GTx-758. Western of the American Urological Association, Monterey, CA, November 3-7, 2013.
179. Getzenberg RH, Matsumoto AM, Coss CC, Hancock M, Si X, **Dalton JT**, Steiner MS. Confirmation of the Free Hormone Hypothesis: Decreases in PSA Correlate with Free Testosterone Rather than Total Testosterone in Men with Advanced Prostate Cancer Treated with GTx-758. 14th Annual Meeting of the Society of Urologic Oncology, December 4-6, 2013.
180. Overmoyer B, Sanz-Altamira P, Taylor R, Hancock ML, **Dalton JT**, Johnston MA & Steiner MS. Enobosarm – a targeted therapy for metastatic androgen receptor positive breast cancer. American Society of Clinical Oncology Annual Meeting. Journal of Clinical Oncology 32 (suppl), Abstract# 568, 2014.
181. Getzenberg RH, Yu EY, Smith JA, Hancock ML, Tutrone R, Flaig TW, Westenfelder KR, Szucs M, **Dalton JT**, and Steiner MS. Low dose GTx-758 decreases free testosterone to levels similar to orchiectomy in men with metastatic castration resistant prostate cancer (mCRPC). 29th Annual European Association of Urology (EAU) Congress, Stockholm, Sweden, April 11 - 15, 2014. European Urology Supplements 13(1):e863, 2014.
182. Yu EY, Getzenberg RH, Smith J, Hancock M, Smith MR, Malkowicz SB, Sieber P, **Dalton JT**, Steiner MS. Optimal testosterone suppression on medical ADT should strive to suppress free testosterone levels, to levels similar to orchiectomy: What is that value? 2014 ASCO GU Cancers Symposium, San Francisco, CA, January 30 – February 1, 2014.
183. Yu EY, Getzenberg RH, Smith J, Hancock ML, Tutrone R, Flaig TW, **Dalton JT**, Steiner MS, Westenfelder KR, Szucs M. The effect of low-dose GTx-758 on free testosterone levels in men with metastatic castration resistant prostate cancer (mCRPC). 2014 Genitourinary Cancers Symposium, American Society of Clinical Oncology, San Francisco, CA, January 30-February 1, 2014, Journal of Clinical Oncology 32, 2014 (supplement 4; abstract 60).

184. Yu EY, Getzenberg RH, , Smith J, Hancock M, Tutrone R, Flaig T, Westenfelder K, Szucs M, **Dalton JT**, Steiner MS. Low dose GTx-758 decreases free testosterone to levels similar to orchiectomy in men with metastatic castration resistant prostate cancer (mCRPC). European Association of Urology, Stockholm, Sweden, April 11-15, 2014.
185. Ponnusamy S, Coss CC, Hwang DJ, McEwan IJ, Watt C, Thiyagarajan T, Ledbetter CK, Patterson AP, Grimes B, Wake RW, Schwartzberg LS, **Dalton JT**, Miller DD, and Narayanan R. Novel Dual-Binding Selective Degraders of Full Length and Splice Variant Androgen Receptors for the Treatment of Castration-Resistant Prostate Cancer. Abstract #LB-S&T-06, American Urological Association, San Diego, CA, May 7, 2016.
186. Getzenberg R, Steiner MS, **Dalton JT**. A novel oral α and β tubulin inhibitor, VERU-111, has potent activity against paclitaxel sensitive and resistant prostate cancer. American Urological Association, San Francisco, CA, May 20, 2018. Abstract #18-4951.

INVITED PRESENTATIONS:

1. National Cancer Institute, Frederick, MD, "Pharmacokinetics and Pharmacodynamics of Intravesical Mitomycin C", September 1993.
2. University of Tennessee, 8th Annual Student Cancer Symposium, Memphis, TN, "Biology and Epidemiology of Prostate Cancer", April 1995.
3. The Ohio State University, Columbus, OH, "Population Pharmacokinetics", May 1995.
4. Hiroshima University Hospital, Hiroshima, Japan. "Pharmacokinetics and Pharmacodynamics of Intravesical Chemotherapy for Bladder Cancer", June 1995.
5. Memphis Chapter of the American Cancer Society, Memphis, TN, "Irreversible Antiandrogens for Prostate Cancer", January 1996.
6. Rotary Club, Lebanon, OH, "Prostate Cancer", July 1996.
7. University of Utah, Salt Lake City, UT, "Molecular Characterization of Androgen Receptor". Aug. 1996
8. Zonagen Inc., Houston, TX, "Therapeutic Applications of Chiral Nonsteroidal Androgen Receptor Ligands", September 1996.
9. Rotary Club, Lebanon, OH, "Impact of Health Care Reform on Drug Development", July 1997.
10. The Population Council, NY, NY, "Nonsteroidal Ligands for the Androgen Receptor", September 1997.
11. Department of Biomedical Engineering, University of Tennessee, Memphis, TN, "Nonsteroidal Ligands for the Androgen Receptor", October 1997.
12. University of Mississippi, University, MS, "Nonsteroidal Ligands for the Androgen Receptor", February 1998.
13. Student Chapter of American Chemical Society, University of Memphis, Memphis, TN, "Therapeutic Applications of Chiral Nonsteroidal Androgen Receptor Ligands", February 1998.
14. Karmanos Cancer Institute and Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI, "Pharmacokinetics and Pharmacodynamics of Intravesical Mitomycin C" and "Nonsteroidal Ligands for the Androgen Receptor", March 1998.
15. Department of Pharmaceutical Sciences and Division of Medical Oncology, University of Colorado, Denver, CO, "Pharmacokinetics and Pharmacodynamics of Intravesical Mitomycin C" and "Nonsteroidal Ligands for the Androgen Receptor", May 1998.
16. Division of Clinical Pharmacology and Division of Medical Oncology, Vanderbilt University, Nashville, TN, "Nonsteroidal Ligands for the Androgen Receptor", June 1998.
17. Departments of Metabolic Diseases and Oncology Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, "Nonsteroidal Agonists and Antagonists for the Androgen Receptor", December 1998.
18. Department of Pharmaceutical Sciences, Washington State University, Pullman, WA, "CYP2C9*3 is Responsible for the Poor Metabolizer Phenotype of Phenytoin and Glipizide", March 1999.
19. Department of Pharmaceutical Sciences, Northeast Louisiana University, Monroe, LA, "Nonsteroidal Ligands for the Androgen Receptor", April 1999.
20. National Cancer Institute, 8th Prouts Neck Meeting on Prostate Cancer, New Visions on Prostate Cancer from Young Investigators, "Molecular Characterization of the Human Androgen Receptor", October 1999.
21. Department of Pharmaceutics, State University of New York at Buffalo, "Nonsteroidal Ligands for the Androgen Receptor", March 2000.
22. American Cancer Society, Gibson County, Tennessee, "Prostate Cancer and Hormones", April 2000.
23. Division of Pharmaceutics, The Ohio State University, "Nonsteroidal Ligands for the Androgen Receptor", June 2000.
24. Departments of Metabolic Diseases and Oncology Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, "Pre-Clinical Pharmacology of Nonsteroidal Androgens", September 2000.
25. Johnson and Johnson Pharmaceutical Research Institute, Raritan, NJ, "Pre-Clinical Pharmacology of Nonsteroidal Androgens", September 2000, November 2002, and January 2003.
26. College of Pharmacy, University of Cincinnati, Cincinnati, OH, "Discovery and Pre-Clinical Pharmacology of Nonsteroidal Androgens", February 2001.
27. Glaxo Smith-Kline Pharmaceuticals, Inc. and GTx, Inc., Memphis, TN, "Discovery and Development of Selective Androgen Receptor Modulators", April 2001.
28. ICOS Pharmaceuticals, Inc., Seattle, WA, "Discovery and Development of Selective Androgen Receptor Modulators", December 2001 and April 2002.

29. Glaxo Smith-Kline Pharmaceuticals, Inc. and GTx, Inc., Memphis, TN, “Pre-Clinical Pharmacology of Andarine”, December 2001, March 2002, and August 2003.
30. Merck Research Laboratories, Philadelphia, PA, “Pre-Clinical Pharmacology of Andarine”, July 2002.
31. Amersham Health and GTx, Inc., Memphis, TN, “Nonsteroidal Androgen Ligands for Treatment and Imaging of Prostate Cancer”, August 2002 and December 2002.
32. Eli Lilly and Company and GTx, Inc., Memphis, TN, “Discovery and Development of Selective Androgen Receptor Modulators”, November 2002.
33. Division of Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, “Discovery and Development of Selective Androgen Receptor Modulators”, November 2002.
34. AstraZeneca Pharmaceuticals and GTx, Inc., Philadelphia, PA, “Discovery and Development of Selective Androgen Receptor Modulators”, December 2002.
35. Columbus Technology Council, Battelle Memorial Institute, “Drug Discovery: The Promise, An Academic Perspective”, February 2003.
36. Novartis AG, East Hanover, NJ, “Pre-Clinical and Clinical Pharmacology of Andarine”, June 2003.
37. Johnson and Johnson, Inc. and GTx, Inc., Memphis, TN. “Pre-Clinical and Clinical Pharmacology of Andarine”, September 2003.
38. Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, "Discovery and Preclinical Pharmacology of Selective Androgen Receptor Modulators", June 2004.
39. Ipsen-Beaufour Pharmaceuticals, Inc., Endocrinology Advisory Board, Paris, France, “Preclinical Pharmacology of Selective Androgen Receptor Modulators”, December 2004.
40. University of Toledo, College of Pharmacy, “Molecular and Preclinical Pharmacology of Selective Androgen Receptor Modulators”, April 2005.
41. Pfizer, Inc., New York, NY, “Discovery and Development of Ostarine, a Promising Selective Androgen Receptor Modulator”, June 2005.
42. United States Anti-Doping Agency (USADA), Fourth Annual USADA Symposium on Anti-Doping Science, Chicago, IL, “Phamacology of Selective Androgen Receptor Modulators”, September 2005.
43. Departments of Pharmaceutics and Pharmacology, University of Utah, “Preclinical and Molecular Pharmacology of Selective Androgen Receptor Modulators”, April 2006.
44. Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan, “Preclinical and Molecular Pharmacology of Selective Androgen Receptor Modulators”, May 9, 2006.
45. 14th NIH SPORE Investigators’ Workshop, Baltimore, MD, “SERMs and SARMs: Emerging Therapies for Prostate Cancer”, July 16-19, 2006.
46. College of Pharmacy, The Ohio State University, Fourth Annual Autumn Symposium Weekend, “Pharmacokinetic Differences Associated with Polymorphisms in the Cytochrome P450 Drug Metabolizing Enzymes”, September 2, 2006.
47. BioPharma in Ohio II, Columbus, OH, “Next Steps: Developing a Statewide Partnership”, February 28, 2007.
48. American Society of Andrology, Tampa, FL,“Development and Potential Uses of Selective Androgen Receptor Modulators (SARMs)”, April 21, 2007.
49. The Endocrine Society, Toronto, Canada, “Selective Androgen Receptor Modulators (SARMs): Preclinical and Clinical Proof-of-Concept Studies”, June 2-5, 2007.
50. Keystone Symposium, Nuclear Receptors, Steroid Sisters, Vancouver, Canada, “Selective Androgen Receptor Modulators (SARMs): Clinical Proof-of-Concept Studies and Molecular Mechanisms of Action”, April 3, 2008.
51. American Society of Andrology, Albuquerque, New Mexico, “Selective Androgen Receptor Modulators (SARMs): Clinical Proof-of-Concept Studies and Molecular Mechanisms of Action”, April 12, 2008.
52. Androgens 2008, Rotterdam, The Netherlands, “Pharmacology of Selective Androgen Receptor Modulators”, October 3, 2008.
53. Ninth International Congress of Andrology, Barcelona, Spain, “Recent Progress with Selective Androgen Receptor Modulators (SARMs)”, March 9, 2009.
54. Androgens 2010, Leuven, Belgium, “The Use of Selective Androgen Receptor Modulators to Improve Lean Body Mass and Muscle Performance in Patients with Cancer Cachexia”. November 26, 2010.
55. American Chemical Society, Denver, Colorado, “Selective Androgen Receptor Modulators: The Discovery and Development of Tissue-Selective Anabolic Therapy”, August 30, 2011.

56. University of Georgia, College of Pharmacy, Athens, GA, "Selective Androgen Receptor Modulators: Academia to Industry, Bench to Bedside", September 21, 2011.
57. Union University, School of Pharmacy, Jackson, TN, "CYP2D6 Pharmacogenomics and Breast Cancer Therapy", February 29, 2012.
58. Summer Research Conference of the American Urological Association and Society for Basic Urologic Research, Linthicum, MD, "Selective Androgen Receptor Modulators (SARMs) as Anabolic Therapy for Muscle Wasting", August 11, 2012.
59. International Conference on Sarcopenia Research, Orlando, FL, "Science of Selective Androgen Receptor Modulators", December 6-7, 2012.
60. St Jude Children's Hospital, Memphis, TN, "Selective Androgen Receptor Modulators for Muscle Wasting in Cancer", February 8, 2013.
61. The Ohio State University, College of Pharmacy Research Day, Columbus, OH, "Selective Androgen Receptor Modulators (SARMs): Bench to Bedside", April 4, 2013.
62. The Endocrine Society, San Francisco, CA, "Androgen Receptor as a Therapeutic Target", June 17, 2013.
63. University of Michigan, College of Pharmacy, Ann Arbor, MI, "Future of Pharmacy Education: Challenges, Opportunities and Priorities for Professional and Graduate Programs", January 21, 2014.
63. The University of Tennessee, Technology Transfer Office and College of Pharmacy, Memphis, TN, "Selective Androgen Receptor Modulators (SARMs): Bench to Bedside, Academia to Industry", March 19, 2014.
64. Pink Palace Museum, Memphis, TN, "Genetics, Race and Medicine: Inheriting Disease and our Response to the Medicines Used to Treat It", April 17, 2014.
65. University of Michigan, "Selective Androgen Receptor Modulators: Academia to Industry, Bench to Bedside?", College of Pharmacy Graduate Student Organization (September 1, 2014), Department of Pharmacology, Medical School (January 28, 2015), and Translational Oncology Program (March 17, 2016).
66. China Pharmaceutical University (May 25), Fudan University (May 26), Sichuan University (May 28), Shenyang Pharmaceutical University (May 29) and Peking University (June 1). "Education and Research in the University of Michigan College of Pharmacy", 2015.
67. University of Nebraska College of Pharmacy, "Selective Androgen Receptor Modulators: Academia to Industry, Bench to Bedside?", April 14, 2016.
68. China Pharmaceutical University, "UM/CPU Dual Degree Program" and "Selective Androgen Receptor Modulators", and Pan-Asia Summit, Shanghai, "Precision Medicines: The Pharmacy Perspective", May 2017.
69. University of Wisconsin, Keynote Speaker, "Selective Androgen Receptor Modulator as Prostate-Sparing Anabolic Therapy", University of Wisconsin and University of Massachusetts – Boston O'Brien Research Center Spring Symposium, May 2017.
70. United States Anti-Doping Agency, "Pharmacokinetics, Disposition and Detection of Doping for Aryl Propionamide SARMs", Orlando, Florida, October 1, 2017.
71. Accreditation Council for Pharmacy Education (ACPE), Board of Directors, "Survey of Pharmacy Curricular Outcomes Assessment (PCOA) Utilization in US Pharmacy Schools", Chicago, IL, January 18, 2018.
72. American Association of Colleges of Pharmacy, Interim Meeting, "Pharmacy Curricular Outcomes Assessment (PCOA)" in session entitled "Standardized Examinations in Pharmacy Education", Long Beach, CA, February 26, 2018.
73. American Pharmacists Association (APhA), "Building a Crooked Stairway in Pharmacy", Rho Chi Lecture Award, Nashville, TN, March 18, 2018.
74. Partnership for Clean Competition, "Selective Androgen Receptor Modulators (SARMs): A New Class of Muscle Building Agents", Webinar, November 28, 2018.
75. University of Florida, College of Pharmacy, "Climbing the Stairs: A Drug Discovery Experience", Gainesville, TN, March 26, 2019.
76. University of Georgia, College of Pharmacy, "Academic Drug Discovery: Clinical Trials and Tribulations", Athens, GA, February 7, 2023.
77. Dr. Nicholas Bodor Distinguished Lectureship, University of Florida, College of Pharmacy, "Academic Drug Discovery: Clinical Trials and Tribulations", Gainesville, FL, April 25, 2023.

RESEARCH FUNDING (total costs):

$15,000	Principal Investigator, "Springboard to Teaching Award", American Foundation for Pharmaceutical Education, 1/1/93 to 12/31/94.
$14,971	Principal Investigator, "Irreversible Non-Steroidal Antiandrogens for the Treatment of Prostate Cancer", American Cancer Society (#IN-176-C), 11/1/93 to 10/31/94.
$12,404	Principal Investigator, "Absolute Bioavailability of 5-Aminolevulinic Acid in the Dog", DUSA Pharmaceuticals, Inc., 11/1/93 to 10/31/94.
$10,000	Principal Investigator, "Pharmacological Evaluation of 4-Substituted Imidazoles", U.S. Army, 6/1/95 to 5/31/96.
$4,750	Principal Investigator, "Nonsteroidal Affinity Ligands for the Androgen Receptor", University of Tennessee, College of Pharmacy, 9/1/95 to 6/30/96.
$99,750	Principal Investigator, "Determinants of Intratumoral Drug Distribution", National Cancer Institute, 1 R15 CA67253-01, 6/1/95 to 5/31/97. Co-P.I.: Atul J. Shukla, Ph.D.
$66,131	Principal Investigator, "Intravesical Stability and Absorption of 5-Aminolevulinic Acid in Dogs", DUSA Pharmaceuticals, Inc., 6/1/96 to 5/31/97. Co-P.I.: Marvin C. Meyer, Ph.D.
$94,620	Co-Investigator (5% effort), "Potential Inactivators of Ribonucleotide Reductase", National Institutes of Health, National Cancer Institute, #1 R15 CA70901-01, 6/1/96 to 5/31/98. Principal Investigator: Michael S. Wolfe, Ph.D.
$3,500	Principal Investigator, "Luminometer Equipment Grant", University of Tennessee, College of Pharmacy, 9/1/97 to 6/30/98.
$5,000	Principal Investigator, "Molecular Biology Equipment Grant", University of Tennessee, College of Pharmacy, 9/1/98 to 6/30/99.
$99,750	Principal Investigator (25% effort), "Nonsteroidal Androgens for Male Contraception", National Institute of Child Health and Human Development, #1 R15 HD35329-01, 6/1/97 to 5/31/99. Co-P.I.: Duane D. Miller
$105,342	Co-Investigator (5% effort), "DNA as Target for Anti-Pneumocystis Carinii Agents", National Institutes of Health, National Institute of Allergy and Infectious Diseases, #1 R15 AI39683-01, 6/1/96 to 5/31/99. Principal Investigator: Isaac O. Donkor, Ph.D.
$67,693	Principal Investigator (5% effort), "An Exploratory Study to Compare the Pharmacokinetics of Three Acetaminophen Formulations – A Three-Way Crossover Study", Alkermes, Inc., 8/31/99 to 10/31/99.
$14,720	Principal Investigator (5% effort), "Pharmacokinetic Evaluation of Levulan after Intravesical Administration in Patients at High Risk for Recurrent Bladder Cancer", 4/15/98 to 12/31/99.
$135,000	Principal Investigator (5% effort), "Corticosteroid Resistance in Patients with Acute Respiratory Distress Syndrome", Baptist Memorial Healthcare Foundation, 9/1/98 to 8/31/01. Co-P.I.: Umberto Meduri.
$220,000	Co-Principal Investigator, "Treatment Strategies for Prostate Cancer", St. Francis of Assisi Foundation, 5/1/96 to 4/30/01. Principal Investigator: Mitchell Steiner, Urology.
$98,841	Principal Investigator, "Pharmacokinetics and Metabolism of GTx-007 in Beagle Dogs", GTx, Inc., Memphis, TN, 3/1/01 to 2/28/02.
$143,604	Principal Investigator, "Pre-Clinical Dose Response Studies of GTx-014, GTx-015, GTx-016, and GTx-017", GTx, Inc., Memphis, TN, 3/1/01 to 2/28/02.
$35,000	Principal Investigator (2% effort), "Synthesis and Biodistribution of Carbon-14 Labeled Nonsteroidal Androgens", GTx, Inc., Memphis, TN, 3/1/02 to 2/28/03.
$496,625	Principal Investigator (25% effort), "Nonsteroidal Affinity Ligands for the Androgen Receptor", National Cancer Institute, #1 R29 CA68096-06, 9/1/97 to 8/31/02, no-cost extension to 8/31/03.
$169,950	Co-Investigator (0% effort), PI: Thomas Rosol, Ph.D., Department of Veterinary Biosciences, Instrumentation Grant to National Institutes of Health, "Measurement of Cells In Vivo: IVIS Light Imaging System", 4/1/03 to 3/31/04.
$2,818,550	Principal Investigator (5% effort), "Discovery and Pre-Clinical Development of Nonsteroidal Androgens and Antiandrogens", GTx, Inc., Memphis, TN, 3/1/01 to 12/31/04.
$552,685	Principal Investigator (10% effort), "Novel Strategy for Prostate Cancer Imaging: Synthesis and Pharmacology of Novel Nonsteroidal Ligands", United States Army, Department of Defense, #PC001480, 3/1/01 to 2/29/04.

$674,402 Co-Investigator (10% effort), PI: Duane D. Miller, Ph.D. (University of Tennessee), “Selective Cytotoxic Phospholipids for Prostate Cancer”, United States Army, Department of Defense, #PC010431, 3/1/02 to 2/29/05.

$1,364,375 Co-Investigator (5% effort), PI: Peter Swaan, Ph.D. (University of Maryland), “Structural Biology of the Apical Bile Acid Transporter”, National Institutes of Health, 12/1/02 to 11/30/04.

$83,776 Principal Investigator (mentor), “Riboflavin carrier protein and riboflavin in breast tumor targeting”, United States Army, Department of Defense, 03/31/04 - 04/12/06.

$2,859,053 Principal Investigator (10% effort), “Pharmacology of Nonsteroidal Androgen Receptor Ligands”, National Institute of Diabetes, Digestive and Kidney Diseases, #1 R01 DK59800-03, 10/1/00 to 9/30/09.

$1,218,010 Co-Principal Investigator, (10% effort), PI: Duane Miller, Ph.D. (University of Tennessee), “Novel Irreversible SARMs for Prostate Cancer”, National Institute of Diabetes, Digestive and Kidney Diseases, #1 R01 DK065227-01, 07/01/03 to 06/30/07.

$4,069,612 Co-Investigator (5% effort), PI: Michael Grever, M.D., Department of Internal Medicine, “Phase I Trials of Anticancer Agents”, National Institutes of Health, 2/1/03 to 1/31/08.

$2,573,918 Co-Investigator, (5% effort), PI: John Byrd, M.D. (Department of Internal Medicine), "Hu1D10 in CLL: Clinical and Laboratory Studies", National Cancer Institute, # 1 R01 CA102504-01, 07/01/03 to 06/30/07.

$1,324,715 Co-Investigator (5% effort), PI: Karl Werbovetz, Ph.D., Division of Medicinal Chemistry, "Simple, Selective Antimitotic Antiparasitic Agents", National Institute of Allergy and Infectious Diseases, 07/01/04-06/30/08.

$590,526 Co-Investigator (5% effort), PI: Thomas S. Lin, M.D. (Department of Internal Medicine), “A Novel Dosing Schedule of Flavopiridol in CLL”, National Cancer Institute, #1 R21CA112947-01, 3/2/2005 to 2/28/2007.

$449,085 Principal Investigator (5% effort) “Tubulin-Destabilizing Bis-Indoles for Advanced Prostate Cancer”, United States Army, Department of Defense, # PC060380, 4/1/07 to 3/31/09.

$5,249,411 Principal Investigator, “Alabama LSAMP: Sustainability of Best Practices for STEM Education and Research”, National Science Foundation, #1619659, 09/01/16-08/31/22.

$50,000,000 Principal Investigator, “The University of Alabama Permanent Endowment Fund to Support the Recruitment and Retention of Exceptional Faculty in Science and Engineering”, U.S. Department of Education, Project #A22-0561, 9/1/22-8/31/23.

$50,000,000 Principal Investigator, “The University of Alabama Permanent Endowment Fund to Support the Recruitment and Retention of Exceptional Faculty in Science and Engineering”, U.S. Department of Education, Project #A23-0488, 6/1/23-5/31/26.

$2,524,467 Principal Investigator, “Alabama LSAMP: Sustainability of Best Practices for STEM Education and Research”, National Science Foundation, #1619659, 07/01/23-06/30/28.

$10,000,000 Principal Investigator, “The University of Alabama Develops an Institute on Policy and Leadership”, U.S. Department of Education, Project #A23-0495, 6/1/2023-5/31/2026.

PATENTS: (Partial list: 102 issued U.S. patents, >500 issued international patents)

Non-Steroidal Agonist Compounds And Their Use In Male Hormone Therapy (S-linked)

- Dalton, Kirkovsky, Miller, Mukherjee. UTRF. Issued United States of America, Patent #6160011 on 12-Dec-00.

Irreversible Non-Steroidal Antagonist Compound and Its Use in The Treatment of Prostate Cancer (S-linked)

- Dalton, Kirkovsky, Miller, Mukherjee. UTRF. Issued United States of America, Patent #6071957 on 6-Jun-00.
- Dalton, Kirkovsky, Miller, Mukherjee. UTRF. Issued United States of America, Patent #US6482861B2 on 19-Nov-02.
- Dalton, Kirkovsky, Miller, Mukherjee. UTRF. Issued United States of America, Patent #7041844 on 9-May-06.
- Dalton, Kirkovsky, Miller, Mukherjee. UTRF. Issued United States of America, Patent #7129377 on 31-Oct-06.

Non-Steroidal Radiolabeled Agonist/Antagonist Compounds and Their use in Prostate Cancer Imaging (S-linked)

- Dalton, Kirkovsky, Miller, Mukherjee. GTx, Inc. Issued United States of America, Patent #6019957 on 1-Feb-00.

Treating Muscle Wasting with Selective Androgen Receptor Modulators (generic methods)

- Dalton, Miller, Steiner, Veverka. UTRF. Issued Armenia, Patent #7921 on 7-Feb-07.
- Dalton, Miller, Steiner, Veverka. UTRF Issued Austria, Patent #1463497 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF Issued Australia, Patent #2002364949 on 7-Jun-07.
- Dalton, Miller, Steiner, Veverka. UTRF Issued Australia, Patent #2007202324 on 29-Oct-09.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Azerbaijan, Patent #7921 on 7-Feb-07.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Belgium, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Bulgaria, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Belarus, Patent #7921 on 7-Feb-07.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Switzerland, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued China, Patent #ZL 02827905.0 on 12-May-10.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Cyprus, Patent #60241270.6 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Czech Republic, Patent #60241270.6 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Germany, Patent #60241270.6 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Denmark, Patent #60241270.6 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Eurasian Office, Patent #7921 on 7-Feb-07.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued European Office, Patent #1463497 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Spain, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Finland, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued France, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued United Kingdom, Patent #7921 on 5-Oct-11
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Georgia, Patent #AP2002005641 on 11-Dec-06.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Greece, Patent #3076832 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Hong Kong, Patent #1068102 on 9-Dec-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Ireland, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Italy, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Japan, Patent #4605557 on 15-Oct-10.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Kyrgyzstan, Patent #7921 on 7-Feb-07.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Republic of Korea, Patent #10-0767317 on 9-Oct-07.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Kazakhstan, Patent #7921 on 7-Feb-07.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Liechtenstein, Patent #1463497 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Luxembourg, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Monaco, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Republic of Moldova, Patent #7921 on 7-Feb-07.

- Dalton, Miller, Steiner, Veverka. UTRF. Issued Mexico, Patent #260118 on 1-Sep-08.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Netherlands, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Portugal, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Russian Federation, Patent #7921 on 7-Feb-07.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Sweden, Patent #7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Tajikistan Patent #7921 on 7-Feb-07.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Turkmenistan Patent #7921 on 7-Feb-07.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Turkey, 7921 on 5-Oct-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued Taiwan R.O.C., Patent #I339118 on 21-Mar-11.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued United States of America, Patent #7547728 on 16-Jun-09
- Dalton, Miller, Steiner, Veverka. UTRF. Issued United States of America Patent #8008348 on 30-Aug-11.

<u>Method of Treating Benign Prostate Hyperplasia with SARMs (BPH (US) and 019 composition (ROW))</u>

- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Austria, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Australia, Patent#2003216174 on 2-Apr-09.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Belgium, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Bulgaria, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner. UTRF. Issued Canada, Patent#2689080 on 5-Jul-11.
- Dalton, Gao, Miller, Steiner. UTRF. Issued Switzerland, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued China, Patent#ZL 03807800.7 on 9-Jun-10.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Cyprus, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Czech Republic, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner. UTRF. Issued Germany, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Denmark, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Eurasian Patent Office, Patent#13399 on 30-Apr-10.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued European Patent Office, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Spain, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Finland, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner. UTRF. Issued France, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued United Kingdom, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Georgia, Patent#P4122 on 6-Nov-07.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Greece, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka, Chung. UTRF. Issued Hong Kong, Patent#HK10681031 on 6-Dec-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Hungary, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Ireland, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Israel, Patent#163380 on 1-Oct-10.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Israel, Patent#202675 on 1-Oct-11.
- Dalton, Gao, Miller, Steiner. UTRF. Issued Italy, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner. UTRF. Issued Japan, Patent#4677516 on 10-Feb-11.
- Dalton, Gao, Miller, Steiner, Veverka, Chung. UTRF. Issued Republic of Korea, Patent#10-1032661 on 26-Apr-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Liechtenstein, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Luxembourg, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Monaco, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Mexico, Patent#269392 on 21-Aug-09.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Netherlands, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner. UTRF. Issued Portugal, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Sweden, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued Turkey, Patent#1480634 on 3-Aug-11.
- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued United States of America, Patent#7776921 on 17-Aug-10.

- Dalton, Gao, Miller, Steiner, Veverka. UTRF. Issued United States of America, Patent#8088828 on 3-Jan-12.

Radiolabeled Selective Androgen Receptor Modulators and Their Use in Prostate Cancer Imaging and Therapy

- Dalton, Kirkovsky, Miller, Mukherjee. UTRF. Issued United States of America, Patent#7344700 on 18-Mar-08.

N-Bridged Selective Androgen Receptor Modulator and Methods of Use

- Dalton, Gao, Markefka, Miller. UTRF. Issued Australia, Patent#2003241583 on 3-Sep-09.
- Dalton, Gao, Markefka, Miller. UTRF. Issued Belarus, Patent#9199 on 28-Dec-07.
- Dalton, Gao, Markefka, Miller. UTRF. Issued China, Patent#ZL 03819545.3 on 9-Sep-09.
- Dalton, Gao, Markefka, Miller. UTRF. IssuedEurasian Patent Office, Patent#9199 on 28-Dec-07.
- Dalton, Gao, Markefka, Miller. UTRF. Issued Georgia, Patent#4191 on 10-Sep-07.
- Dalton, Gao, Markefka, Miller. UTRF. Issued India , Patent#238907 on 25-Feb-10.
- Dalton, Gao, Markefka, Miller. UTRF. Issued Kazakhstan, Patent#9199 on 28-Dec-07.
- Dalton, Gao, Markefka, Miller. UTRF. Issued Republic of Moldova, Patent#9199 on 28-Dec-07.
- Dalton, Gao, Markefka, Miller. UTRF. Issued Mexico, Patent#250433 on 16-Oct-07.
- Dalton, Gao, Markefka, Miller. UTRF. Issued Russian Federation, Patent#9199 on 28-Dec-07.
- Dalton, Gao, Markefka, Miller. UTRF. Issued Tajikistan, Patent#9199 on 28-Dec-07.
- Dalton, Gao, Markefka, Miller. UTRF. Issued Turkmenistan, Patent#9199 on 28-Dec-07.
- Dalton, Gao, Markefka, Miller. UTRF. Issued United States of America, Patent#7022870 on 4-Apr-06.
- Dalton, Gao, Markefka, Miller. UTRF. Issued United States of America, Patent#7741371 on 2-Jun-10.

Heterocyclic Selective Androgen Receptor Modulators and Methods of Use Thereof

- Dalton, Miller. UTRF. Issued Australia, Patent#2003287076 on 16-Jul-09.
- Dalton, Miller. UTRF. Issued United States of America, Patent#7214693 on 8-May-07.

Methylene-Bridged Selective Androgen Receptor Modulators and Methods of Use Thereof

- Dalton, Miller. UTRF. Issued Australia, Patent#2003287077 on 4-Jan-08.
- Dalton, Miller. UTRF. Issued United States of America, Patent#7253210 on 7-Aug-07.

Selective Androgen Receptor Modulators and Methods of Use Thereof

- Dalton, He, Miller, Yin. UTRF. Issued Austria, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Austria, Patent#E423092 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Austria, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Australia, Patent#2001285230 on 11-May-07.
- Dalton, He, Miller, Yin. UTRF. Issued Australia, Patent#2003287074 on 25-Mar-10.
- Dalton, He, Miller, Yin. UTRF. Issued Australia, Patent#2006201538 on 5-Jun-03.
- Dalton, He, Miller, Yin. UTRF. Issued Australia, Patent#2007201969 on 7-Oct-10.
- Dalton, He, Miller, Yin. UTRF. Issued Belgium, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Belgium, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Belgium, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Bulgaria, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Canada, Patent#2420279 on 19-Jul-11.
- Dalton, He, Miller, Yin. UTRF. Issued Canada, Patent#2538095 on 22-Dec-09.
- Dalton, He, Miller, Yin. UTRF. Issued Switzerland, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Switzerland, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Switzerland, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued China, Patent#ZL 01817889.8 on 7-Oct-05.
- Dalton, He, Miller, Yin. UTRF. Issued China, Patent#ZL 200510067494.6 on 12-May-10.
- Dalton, He, Miller, Yin. UTRF. Issued Cyprus, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Cyprus, Patent#CY1110459 on 18-Feb-09.

- Dalton, He, Miller, Yin. UTRF. Issued Cyprus, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Czech Republic, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Germany, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Germany, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Germany, Patent#60327456.0-08 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Denmark, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Denmark, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Denmark, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Eurasian Patent Office, Patent#7101 on 30-Jun-06.
- Dalton, He, Miller, Yin. UTRF. Issued Eurasian Patent Office, Patent#11744 on 2-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Eurasian Patent Office, Patent#14224 on 29-Oct-10.
- Dalton, He, Miller, Yin. UTRF. Issued European Patent Office, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued European Patent Office, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued European Patent Office, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Spain, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Spain, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Spain, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Finland, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Finland, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Finland, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued France, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued France, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued France, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued United Kingdom, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued United Kingdom, Patent#1491524v18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued United Kingdom, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Hong Kong, Patent#1062011 on 4-May-07.
- Dalton, He, Miller, Yin. UTRF. Issued Hong Kong, Patent#1072243 on 21-Apr-10.
- Dalton, He, Miller, Yin. UTRF. Issued Hong Kong, Patent#1080070 on 24-Dec-09.
- Dalton, He, Miller, Yin. UTRF. Issued Croatia, Patent#P20030118 on 12-Jun-08.
- Dalton, He, Miller, Yin. UTRF. Issued Hungary, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Ireland, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Ireland, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Ireland, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued India, Patent#220083 on 15-May-08.
- Dalton, He, Miller, Yin. UTRF. Issued Italy, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Italy, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Italy, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Japan, Patent#4764719 on 17-Jun-11.
- Dalton, He, Miller, Yin. UTRF. Issued Japan, Patent#4694529 on 4-Mar-11.
- Dalton, He, Miller, Steiner, Veverka, Yin. UTRF Issued Republic of Korea, Patent#10-1068779 on 23-Sep-11.
- Dalton, He, Miller, Yin. UTRF. Issued Republic of Korea, Patent#10-1069612 on 27-Sep-11.
- Dalton, He, Miller, Yin. UTRF. Issued Lithuania, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Lithuania, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Luxembourg, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Luxembourg, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Luxembourg, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Monaco, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Monaco, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Monaco, Patent#1558565 on 29-Apr-09.

- Dalton, He, Miller, Yin. UTRF. Issued Mexico, Patent#239893 on 30-Aug-06.
- Dalton, He, Miller, Yin. UTRF. Issued Mexico, Patent#266085 on 16-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Mexico, Patent#280969 on 12-Nov-10.
- Dalton, He, Miller, Yin. UTRF. Issued Mexico, Patent#281366 on 24-Nov-10
- Dalton, He, Miller, Yin. UTRF. Issued Netherlands, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Netherlands, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Netherlands, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Portugal, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Portugal, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Portugal, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Romania, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Romania, Patent#1055638 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Russian Federation, Patent#7101 on 13-Mar-06.
- Dalton, He, Miller, Yin. UTRF. Issued Russian Federation, Patent#11744 on 30-Jun-09.
- Dalton, He, Miller, Yin. UTRF. Issued Sweden, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Sweden, Patent#1491524 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Sweden, Patent#1558565 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Turkey, Patent#1401801 on 2-Nov-06.
- Dalton, He, Miller, Yin. UTRF. Issued Turkey, Patent#TR200903150 T4 on 18-Feb-09.
- Dalton, He, Miller, Yin. UTRF. Issued Turkey, Patent#200905553 on 29-Apr-09.
- Dalton, He, Miller, Yin. UTRF. Issued Taiwan R.O.C., Patent#I332955 on 10-Nov-10.
- Dalton, He, Miller, Yin. UTRF. Issued United States of America, Patent#6492554 on 10-Dec-02.
- Dalton, He, Miller, Steiner, Veverka, Yin. UTRF. Issued United States of America, Patent#7026500 on 11-Apr-06.
- Dalton, He, Miller, Yin. UTRF. Issued United States of America, Patent#6569896 on 27-May-03.
- Dalton, He, Miller, Yin. UTRF. Issued United States of America, Patent#7759520 on 20-Jul-10.
- Dalton, He, Miller, Yin. UTRF. Issued United States of America, Patent#7205437 on 17-Apr-07.
- Dalton, He, Miller, Yin. UTRF. Issued United States of America, Patent#7518013 on 14-Apr-09.
- Dalton, He, Miller, Steiner, Veverka, Yin. UTRF. Issued United States of America, Patent#6838484 on 4-Jan-05.
- Dalton, He, Miller, Yin. UTRF. Issued United States of America, Patent#6995284 on 7-Feb-06.
- Dalton, He, Miller, Yin. UTRF. Issued United States of America, Patent#6998500 on 14-Feb-06.

<u>Multi-Substituted Selective Androgen Receptor Modulators and Methods of Use Thereof</u>

- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Issued Australia, Patent#2003216153 on 8-May-08.
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Issued Australia, Patent#2008201811 on 14-Jul-11.
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Issued China, Patent#ZL03809606.4 on 15-Jun-11.
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Issued Georgia, Patent#4209 on 10-Oct-07.
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Allowed Hong Kong.
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Issued India, Patent#227989 on 27-Jan-09
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Issued Republic of Korea, Patent#10-1088352 on 24-Nov-11.
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Allowed Mexico.
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Issued Taiwan R.O.C. , Patent#I338678 on 11-Mar-11
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Issued United States of America, Patent#7705182 on 27-Apr-10.
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Issued United States of America, Patent#7803970 on 28-Sep-10.
- Chen, Dalton, Hwang, Miller, Steiner, Veverka. UTRF. Allowed United States of America.

Large-Scale Synthesis of Selective Androgen Receptor Modulators

- Chung, Dalton, Miller, Steiner, Veverka. UTRF. Allowed Australia.
- Chung, Dalton, Miller, Steiner, Veverka. UTRF. Issued China, Patent#ZL200480006821.0 on 8-Dec-10.
- Chung, Dalton, Miller, Steiner, Veverka. UTRF. Issued Japan, Patent#4603528 on 8-Oct-10.
- Chung, Dalton, Miller, Steiner, Veverka. UTRF. Allowed Mexico.
- Chung, Dalton, Miller, Steiner, Veverka. UTRF. Allowed Taiwan R.O.C.
- Chung, Dalton, Miller, Steiner, Veverka. UTRF. Issued United States of America, Patent#7968721 on 28-Jun-11.

Treating Bone-Related Disorders with Selective Androgen Receptor Modulators

- Dalton, Kearbey, Miller, Steiner, Veverka. UTRF. Issued Australia, Patent#2004281708 on 2-Jun-11.
- Dalton, Kearbey, Miller, Steiner, Veverka. UTRF. Issued China, Patent#ZL200480023295.9 on 3-Feb-10.
- Dalton, Kearbey, Miller, Steiner, Veverka. UTRF. Issued Eurasian Patent Office , Patent#13738 on 6-Apr-10.

Selective Androgen Receptor Modulators, Analogs and Derivatives Thereof and Uses Thereof (3rd Gen SARMs)

- Bohl, Dalton, Miller, Mohler, Rakov. GTx, Inc. Issued United States of America, Patent#8110562 on 7-Feb-12.

Solid Forms of Selective Androgen Receptor Modulators

- Ahn, Bird, Dalton, Dickason, Hong. GTx, Inc. Issued United States of America, Patent#7977386 on 12-Jul-11.
- Ahn, Bird, Dalton, Dickason, Hong. GTx, Inc. Issued United States of America, Patent#7968603 on 28-Jun-11.

SARMs and Methods of Use Thereof

- Dalton, Miller. UTRF. Issued United States of America, Patent#7772443 on 10-Aug-10

Selective Androgen Receptor Modulators and Methods of Use Thereof (SARM composition and methods)

- Dalton, Miller, Veverka. UTRF. Issued Australia, Patent#2005251781 on 13-Sep-07.
- Dalton, Miller, Veverka. UTRF. Issued Canada, Patent#2543827 on 9-Mar-10.
- Dalton, Miller, Veverka. UTRF. Issued Eurasian Patent Office, Patent#11306 on 23-Nov-08.
- Dalton, Miller, Veverka. UTRF. Allowed European Patent Office.
- Dalton, Miller, Veverka. UTRF. Issued Georgia, Patent#4851 on 26-Nov-09.
- Dalton, Miller, Veverka. UTRF. Issued India, Patent#246393 on 25-Feb-11.
- Dalton, Miller, Veverka. UTRF. Issued Japan, Patent#4201818 on 17-Oct-08.
- Dalton, Miller, Veverka. UTRF. Issued Mexico, Patent#268988 on 4-Aug-09.
- Dalton, Miller, Veverka. UTRF. Issued Ukraine, Patent#87852 on 25-Aug-09.
- Dalton, Miller, Veverka. UTRF. Issued United States of America, Patent#7622503 on 24-Nov-09.
- Dalton, Miller, Steiner, Veverka. UTRF. Issued United States of America, Patent#7855229 on 21-Dec-10
- Dalton, Miller, He, Yin. UTRF. Issued United States of America, Patent#7919647 on 5-Apr-11.
- Dalton, Miller. UTRF. Issued United States of America, Patent#7645898 on 12-Jan-10.
- Dalton, Miller, Veverka. UTRF. Issued Uzbekistan, Patent#IAP04176 on 14-May-10.

Nuclear Receptor Binding Agents

- Barrett, Dalton, He, Hong, Miller, Mohler, Narayanan, Wu. GTx, Inc. Allowed United States of America.
- Dalton, Narayanan, Yepuru. GTx, Inc., Patent#9,623,021B2 on 18-Apr-17.

Substituted Acylanilides and Methods of Use Thereof

- Dalton, Miller. UTRF. Issued United States of America, Patent#8080682 on 20-Dec-11.

Compounds for the Treatment of Cancer

- Ahn, Chen. Dalton, CM Li, W Li, Miller. UTRF and Oncternal, Inc., Issued United State of America, Patent#10,865,196 on 15-Dec-20.
- Ahn, Chen. Dalton, CM Li, W Li, Miller. UTRF and Oncternal, Inc., Issued Israel, Patent#IL209995A on 08-Mar-17.

TEACHING EXPERIENCE:

Spring 1991	Co-Director and Lecturer, PHAR 894a, Disposition of Xenobiotics in Biological Systems, 3 credit hours, Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University. Course Director: Jessie L.-S. Au, Pharm.D, Ph.D. Ten graduate students in class. 10 contact hours/quarter.
Spring 1992	Lecturer, PHAR 603, Chemotherapy of Cancer, 3 credit hours, College of Pharmacy, The Ohio State University. Course Director: Jessie L.-S. Au, Pharm. D., Ph.D. Twenty-five students in class. 10 contact hours/quarter.
Fall 1993	Co-Director and Lecturer, PHSC 211, Biopharmaceutics, 2 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. Course Director: Marvin C. Meyer, Ph.D. Seventy students in class. 10 contact hours/semester.
Fall 1993	Group Facilitator, CLPH 112, Critical Thinking, 1 credit hour, Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee. Course Director: Dick R. Gourley, Pharm.D. Approximately 10 students in class. Responsible for one 2 hour group discussion per week, 32 contact hours/semester.
Fall 1994	Co-Director and Lecturer, PHSC 211, Biopharmaceutics, 2 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. Course Director: Marvin C. Meyer, Ph.D. Seventy students in class. 10 contact hours/semester.
Spring 1995	Director and Lecturer, PHAC 813, Advanced Pharmacokinetics, 4 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. Course Co-Director: John J. Lima, Pharm.D. Five graduate students. 24 contact hours/semester.
Fall 1995	Co-Director and Lecturer, PHSC 211, Biopharmaceutics, 2 credit hours, Department of Pharmaceutical Sciences, University of Tennessee. Course Director: Marvin C. Meyer, Ph.D. Seventy students in class. 10 contact hours/semester.
Fall 1995	Recitation Leader, CLPH 315, Applied Pharmacokinetics, 3 credit hours, Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee. Course Director: John J. Lima, Pharm.D. Twelve students in recitation section. Responsible for one 2 hour recitation per week, 32 contact hours/semester.
Fall 1996	Lecturer and Recitation Leader, CLPH 315, Applied Pharmacokinetics, 3 credit hours, Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee. Course Director: John J. Lima, Pharm.D. Seventy students in class, fourteen students in recitation. Responsible for six lectures and one 2 hour recitation section per week, 38 contact hours/semester.
Spring 1997	Co-Director and Lecturer, PHSC 221, Pharmacokinetics, 3 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. Course Director: John J. Lima, Pharm.D. One hundred students in class, thirteen students in recitation. Responsible for 10 lectures and one 2 hour recitation section per week, 42 contact hours/semester.
Spring 1997	Director and Lecturer, PHAC 813, Advanced Pharmacokinetics, 4 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. Course Co-Director: John J. Lima, Pharm.D. Ten graduate students. 24 contact hours/semester.

Fall 1997	Recitation Leader, CLPH 315, Applied Pharmacokinetics, 3 credit hours, Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee. Course Director: Julie Johnson, Pharm.D. One hundred students in class, fourteen students in recitation. Responsible for one 2 hour recitation per week, 38 contact hours/semester.
Fall 1997	Lecturer, PHAC 817, Drug Metabolism, 3 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. Course Director: Mary V. Relling, Pharm.D. Fifteen graduate students. Responsible for 2 lectures (cytochrome P450 2C9 and NADPH-quinone oxidoreductase), 3 contact hours/semester.
Spring 1998	Director, PHSC 221, Pharmacokinetics, 3 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. One hundred students in class, thirteen students per recitation. 39 contact hours/semester.
Spring 1999	Director, PHSC 221, Pharmacokinetics, 3 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. One hundred students in class, twelve students per recitation. 42 contact hours/semester.
Fall 1999	Director, PHAC 813, Advanced Pharmacokinetics, 4 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. Course Co-Director: Bernd Meibohm, Ph.D. Nine graduate students. 24 contact hours/semester.
Fall 1999	Director, PHAC 819/919 and MEDC 819/919, Seminars in Pharmaceutical Sciences, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee.
Spring 2000	Director, PHSC 221, Pharmacokinetics, 3 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. One hundred students in class, twelve students per recitation. 42 contact hours/semester.
Spring 2000	Lecturer, PHAC 817, Drug Metabolism, 3 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee. Course Director: Mary V. Relling, Pharm.D. Five graduate students. Responsible for 2 lectures (cytochrome P450 2C9 and NADPH-quinone oxidoreductase), 3 contact hours/semester.
Spring 2000	Lecturer, BIOM 811, Mathematical Modeling of Biological Systems, Department of Biomedical Engineering, College of Medicine, University of Tennessee. Course Director: Mohammed Kiani, Ph.D. Four graduate students. Responsible for 2 lectures (Compartmental and Physiologic Modeling), 3 contact hours/semester.
Winter 2001	Director, PHAR 622, Drug Delivery II, 3 credit hours, Division of Pharmaceutics, College of Pharmacy, The Ohio State University. Eighty-three students in class, 40 contact hours per quarter.
Autumn 2001	Director, Pharmacy 894e, Drug Metabolism, 4 credit hours, Division of Pharmaceutics, College of Pharmacy, The Ohio State University. Twenty-eight students in class, 20 contact hours per quarter. Course Co-Director: Kenneth Chan, Ph.D.
Winter 2002	Director, Pharmacy 622, Drug Delivery II, 3 credit hours, Division of Pharmaceutics, College of Pharmacy, The Ohio State University. One hundred and one students in class, 40 contact hours per quarter.

Fall 2002	Lecturer, Pharmacy 802, Advanced Pharmacokinetics, 3 credit hours, Division of Pharmaceutics, College of Pharmacy, The Ohio State University. Fifteen students in class, 4 contact hours per quarter (10% of course).
Winter 2003	Director, Pharmacy 622, Drug Delivery II, 3 credit hours, Division of Pharmaceutics, College of Pharmacy, The Ohio State University. One hundred and fifteen students in class, 40 contact hours per quarter.
Winter 2004	Director, Pharmacy 622, Drug Delivery II, 3 credit hours, Division of Pharmaceutics, College of Pharmacy, The Ohio State University. One hundred and thirteen students in class, 20 contact hours per quarter.
Fall 2004	Director, Pharmacy 621, Drug Delivery I, 3 credit hours, Division of Pharmaceutics, College of Pharmacy, The Ohio State University. One hundred and nineteen students in class, 20 contact hours per quarter.
Spring 2018	Director, Pharmaceutical Sciences 737, Entrepreneurship in Pharmacy, 1.5 credit hours, Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 28 students, 21 contact hours.

POSTDOCTORAL TRAINEES:

Katsushi Miyake, Ph.D., Supervisor of Drug Research Room, Department of Pharmaceutical Sciences, Hiroshima University Hospital, Hiroshima, Japan. March- August, 1993.

Yasuhiro Kimura, Ph.D., Research Pharmacist, Department of Pharmaceutical Sciences, Hiroshima University Hospital, Hiroshima, Japan. October 1996-April 1997.

Oleg Bulgakov, Ph.D., Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia, September 1998 to October 2000.

Alexander Vysokanov, Ph.D., Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, Russia, November 1998 to January 2000.

Donghua Yin, Ph.D., Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN, November 2000-2001.

Lisheng Wang, Ph.D., Division of Pharmaceutics, The Ohio State University, Columbus, OH, August 2001 to June 2004.

Di Wu, Ph.D., Division of Pharmaceutics, The Ohio State University, Columbus, OH, 2001 to 2005.

Zengru Wu, Ph.D., Division of Pharmaceutics, The Ohio State University, Columbus, OH, February 2002 to 2006.

Wenqing Gao, Ph.D., Division of Pharmaceutics, The Ohio State University, Columbus, OH, June 2004 to 2006.

Casey, Bohl, Ph.D., Division of Pharmaceutics, The Ohio State University, Columbus, OH, 2005 to 2007.

Mitchell Phelps, Ph.D., Division of Pharmaceutics, The Ohio State University, Columbus, OH, 2006 to 2008.

Yun Wang, Ph.D., Division of Pharmaceutics, The Ohio State University, Columbus, OH, 2007-2008.

GRADUATE STUDENT TRAINEES:

Arnab Mukherjee, 1994 to 1998. Ralph R. Braund Young Investigator in Cancer Research at the University of Tennessee in 1996, Dissertation Title: “Pharmacokinetics and Binding of Nonsteroidal Androgen Receptor Ligands”, Awarded Ph.D. in 1998. Current: Executive Director of Clinical Pharmacology, Pfizer Inc., Groton, CT.

Diansong Zhou Fall 1995 to 1999. Thesis Title: Sensitization of Human Tumor Cells to Cyclophosphamide using Cytochrome P450 2C9 Gene Transfer; Awarded M.S. in June 1999. Current: Senior Director, Senior Pharmacometric Leader, AstraZeneca, Wilmington, DE.

Zixin ‘John’ Zhu, Spring 1997 to 2000. Dissertation Title: “Recombinant Expression And Mass Spectrometric Characterization Of The Human Androgen Receptor And Its Ligand-Binding Domain”; Awarded Ph.D. in December 2000. Current: Pharmacologist, GlaxoSmithKline, Inc., Philadelphia, PA.

Charles R. Yates, 1997 to 2000. Ralph R. Brand Young Investigator in Cancer Research at the University of Tennessee in 1998, Fellow of the American Foundation for Pharmaceutical Education, Dissertation Title: “Methylprednisolone In Acute Respiratory Distress Syndrome: Insight Into Inefficacy”. Awarded Ph.D. in December 2000. Current: Principal Scientist, National Center for Natural Products Research, Oxford, MS.

Donghua Yin, Fall 1996 to 2000. Dissertation Title:“Pharmacokinetics and Metabolism of Nonsteroidal Androgens”; Awarded Ph.D. in December 2000. Current: Vice President, Head of Clinical Pharmacology, Pfizer Inc., La Jolla, CA.

Jeffrey Kearbey, Fall 1999 to 2004. Dissertation Title: "Evaluation of a Nonsteroidal Selective Androgen Receptor Modulator as a Treatment for Osteoporosis"; Awarded Ph.D. in June 2004. Current: Scientific Director, Abbvie Laboratories, Chicago, IL.

Wenqing Gao, Fall 2000 to 2004. Dissertation Title: "Pharmacology of Selective Androgen Receptor Modulators (SARMs)"; Awarded Ph.D. in June 2004. Current: Senior Scientific Director, Abbvie Laboratories, Chicago, IL.

Huiping Xu, Spring 1999 to 2004. Dissertation Title: "Electrophilic Nonsteroidal Androgen Receptor Ligands for Prostate Cancer"; Awarded Ph.D. in August 2004. Current: Director of Clinical Pharmacology, Pfizer, Inc., La Jolla, CA.

Scott Fisher, Winter 2002 to 2004. Thesis Title: “Identification of Structure-Activity Relationships of Selective Androgen Receptor Modulators in Preclinical Animal Models”, Awarded M.S. in December 2004. Awarded Ph.D. from University of Maryland 2009. Current: Director, Academic and Network Collaborations, Exact Sciences, Madison, WI.

Casey Bohl, Fall 2001 to 2005. Dissertation Title: “Structural Characterization of Androgen Receptor Interactions with Nonsteroidal Ligands”; Awarded Ph.D. in June 2005. Current: Radiologist, Charlotte, NC.

Jiyun Chen, Fall 2001 to 2005. Dissertation Title: “Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators for Hormonal Male Contraception”; Awarded Ph.D. in June 2005. Presidential Fellow of The Ohio State University 2005. Current: Associate Director of Clinical Pharmacology, Medivation, San Francisco, CA.

Na Guan, Fall 2002 to 2005. Non-Thesis Master of Science, August 2005. Current: Toxicologist, Bayer, Inc., Germany.

Mitchell Phelps, Spring 2003 to 2005. Dissertation Title: “Novel approaches for characterizing the riboflavin transport and trafficking mechanism and its potential as a target in breast cancer”, Awarded Ph.D. in Biophysics in December 2005. Current: Professor at The Ohio State University, Columbus, OH.

Eunju Hurh, Winter 2002 to 2005. Dissertation Title: "In Vitro and In Vivo Pharmacologic Evaluation of Novel Lysophospholipid Analogs as Anticancer Agents", Awarded Ph.D in Pharmaceutics in December 2005. Current: Associate Director, Novartis Pharmaceuticals, Boston, MA.

Jun Yang, Winter 2001 to 2005. Dissertation Title: "Approaches to Prostate Cancer Imaging and Therapy: Use of Pharmacokinetics, Metabolism, and Biodistribution to Identify New Drugs", Awarded Ph.D. in Pharmaceutics in December 2005. Current: Senior Reviewer, FDA, Silver Springs, MD.

Juhyun Kim, Winter 2002 to 2006. Dissertation Title: "Pharmacokinetics, Metabolism, and Pharmacologic Activities of Nonsteroidal Selective Androgen Receptor Modulators and Their Potential Application to Osteoporosis. Awarded Ph.D. in Pharmaceutics in December 2006. Current: Reviewer, FDA, Silver Springs, MD.

Natalie Goldberger, Summer 2002 to 2008. Dissertation Title: "A Comprehensive Investigation into the Molecular Mechanism Responsible for Selective Androgen Receptor Modulator (SARM) Tissue Selectivity". Awarded Ph.D. in Biophysics in June 2008. Current: Senior Medical Science Liaison, Eisai, Atlanta, GA.

Joyce Lai, Winter 2004 to 2008. Dissertation Title: "Phosphatase and tensin homolog deleted on chromosome Ten (PTEN) as a molecular target in lung epithelial wound repair and protection". Co-advised with Dr. Daren Knoell. Awarded Ph.D. in Pharmaceutics in June 2008. Current: Reviewer, FDA, Silver Springs, MD.

Qing Liu, Winter 2005 to 2008. Dissertation Title: "Targeting Protein Phosphatase 2a as a Therapeutic Strategy for Chronic Lymphocytic Leukemia." Co-advised with Dr. John Byrd. Awarded Ph.D. in Pharmaceutics in June 2008. Current: Senior Reviewer, FDA, Silver Springs, MD.

Robert S. Kidd, Pharm.D., 1994-2008. Dissertation Title: "The Development and Validation of a Novel Genetic-Based Warfarin Dosing Regimen". Awarded Ph.D. in Pharmaceutics in August 2008. Current: Dean and Professor, College of Pharmacy, Shenandoah University.

Christopher C. Coss, Summer 2004 to 2008. Dissertation Title: "Selective Androgen Receptor Modulator (SARM): Androgen Therapy Revisited". Awarded Ph.D. in Pharmaceutics in December 2008. Current: Assistant Professor, The Ohio State University, Columbus, OH.

Amanda Jones, Fall 2005-2010. Dissertation Title: "Molecular and Preclinical Pharmacology of Nonsteroidal Androgen Receptor Ligands". Awarded Ph.D. in Pharmaceutics in June 2010. Current: Reviewer, FDA, Silver Springs, MD.

Chien-Ming Li, Fall 2005 to 2010. Dissertation Title: "In Vitro and In Vivo Pharmacology of 4-Substituted Methoxybenzoyl-Aryl- Thiazoles (SMART) and 2-Arylthiazolidine-4-Carboxylic Acid Amides (ATCAA)". Awarded Ph.D. in Pharmaceutics in August 2010. Current: Scientist, Global Blood Therapeutics, San Francisco, CA.

Sunjoo Ahn, Fall 2005 to 2010. Dissertation Title: "Novel Antimitotic Compounds with Potent In Vitro and In Vivo Antitumor Effects: the Use of Pharmacokinetics, Metabolism, Efficacy, and Toxicity Studies". Awarded Ph.D. in Pharmaceutics in August 2010. Current: Senior Research Investigator, Korea Research Institute of Chemical Technology, Deajeon, South Korea.

GRADUATE STUDENT DISSERTATION COMMITTEES:

University of Tennessee

Shilpa S. Thosar	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 1993 - 1996, Awarded Ph.D. in Pharmaceutics, December 1996.
Noah M. Roth	Department of Biomedical Engineering, College of Medicine, Member, 1995 – 1997, Awarded M.S. in Biomedical Engineering, December 1997.
Robert S. Kidd	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 1994 – 1998, Awarded M.S. in Pharmaceutics, June 1998.
Wei-Ping Zheng	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 1995 – 1999, Awarded Ph.D. in Medicinal Chemistry, June 1999.
Vinh Nguyen	Department of Biomedical Engineering, College of Medicine, Member, 1997 – 1999, Awarded M.S. in Biomedical Engineering, June 1999.
Chengan Du	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 1996 – 1999, Awarded Ph.D. in Pharmaceutics, December 1999.
Daphne D. Herron	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 1995 – 1999, Awarded Ph.D. in Pharmaceutics, June 2000.
Hui Li	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 1995 – 2000, Awarded Ph.D. in Medicinal Chemistry, December 2000.
Yali He	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 1996 –2000, Awarded Ph.D. in Medicinal Chemistry, December 2000.
Mathew Edick	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 1999 – 2000.
Lee Sanders	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 1999 – 2000.
Mark Leggas	Department of Biomedical Engineering, College of Medicine, Member, 1999- 2000.
Craig Marhefka	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 1997 – 2001. Awarded Ph.D. in Medicinal Chemistry, December 2001.
Sonia Bedi	Department of Pharmaceutical Sciences, College of Pharmacy, Member, 2008 – 2010.

The Ohio State University

Donald Black	Graduate School Representative, Department of Physiology, Ph.D. awarded March 2001.
Roger Chapman	Graduate School Representative, Department of Systems and Industrial Engineering, Ph.D. awarded March 2002.
Teng-Kuang Yeh	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded June 2002.
Jing Liu	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded June 2002.
Michael A. Gosselin	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded August 2002.
Danny Chen	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded Dec. 2002.
Yilong Zhang	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded Dec. 2002.
Yong Cui	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded June 2003.
Max Tsai	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded Dec. 2003.
Zhihong Zhang	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded June 2004.
Hui Zheng	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded June 2004.
Carmen Hernandez	Division of Pharmaceutics, College of Pharmacy, Member, M.S. awarded June 2004.
Jin Xiao	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded Dec. 2004.
Jonghan Kim	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded Dec. 2004.
Praveen Bahadduri	Graduate Program in Biophysics, Member, 2002 to present.
Leijun Hu	Division of Pharmaceutics, College of Pharmacy, Member, 2003.
Greg Lyness	Division of Pharmaceutics, College of Pharmacy, Member, 2002.
Xiaobin Zhao	Division of Pharmaceutics, College of Pharmacy, Member, 2005.
Eunjoo Lee	Division of Pharmaceutics, College of Pharmacy, Member, 2006.
Amy Foraker	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded March 2007.
Carmen Hernandez	Division of Pharmaceutics, College of Pharmacy, Member, Ph.D. awarded June 2007.

University of Michigan
Vernon Lalone Department of Pharmaceutical Sciences, College of Pharmacy, Ph.D. awarded August 2019.

UNDERGRADUATE STUDENT TRAINING:

Robin Mottern, 1993 - 1994. Awarded Pharm.D. in 1996. Worked full-time on research project related to androgen receptor binding.

Pratichee Shukla, 1994 - 1996. Awarded Pharm.D. in 1997 at Xavier University, New Orleans, LA. Worked summers on projects including adrenergic receptor binding (1994), analytical method for paclitaxel (1995), and pharmacokinetics of nonsteroidal ligands (1996).

Ash Jha, Summer 1996. B.S. in Biology from University of Memphis in 1995. Worked full-time during summer on research project to examine the intravesical stability and absorption of 5-aminolevulinic acid in beagle dogs. Admitted to College of Medicine at the University of Tennessee in 1997.

Christina Bradley, Summer 1997. Senior student in Chemistry program at Christian Brothers University, Memphis, TN. Worked full-time during summer on research project to examine the androgen receptor binding affinity and transcriptional activation of novel nonsteroidal ligands for prostate cancer. Admitted to Pharm.D. program at University of Tennessee in 2001.

Michele Marvel, 1996 to 1998. Senior student in Biology at the University of Memphis. Worked full-time during summer on research project to determine anticancer efficacy of taxol when delivered in controlled-release injectable gels. Admitted to College of Pharmacy at University of Tennessee in 1997.

Donna McDougal, Summer 1998. Junior student in Biology program at Rust College. Worked full-time during summer on research project to examine the androgen receptor binding affinity of novel nonsteroidal ligands for prostate cancer. Admitted to PharmD program in Fall 2001.

Kimberly Dickerson, Summer 1999. P-3 student in Pharmacy at Xavier University, College of Pharmacy. Worked full-time during summer on research project to examine the role of P-glycoprotein transport in corticosteroid resistance.

Salah Gammouh, Fall 2001. P-2 student in Pharm.D. program at The Ohio State University, College of Pharmacy. Worked part-time for undergraduate credit (Pharmacy 693) on a project to examine the pharmacologic effects of nonsteroidal androgens.

Josh Reardon, Winter 2002 to 2003. Senior student in B.S. in Pharmaceutical Sciences at The Ohio State University, College of Pharmacy. Worked part-time for undergraduate credit (Pharmacy 693) on a project to examine the effects of nonsteroidal androgens on 5α-reductase. Admitted to Pharm.D. program in Fall 2002.

Arpi Sakadjian, Spring 2002 to 2003. Junior student in Pharmaceutical Sciences at The Ohio State University, College of Pharmacy. Worked part-time for undergraduate credit (Pharmacy 693) on a project to examine the effects of metabolism of nonsteroidal androgens by cytochrome P450s. Admitted to Pharm.D. program in Fall 2003.

Kimberly Buckley, Summer 2003 to Summer 2004. Junior undergraduate student in molecular genetics. Worked part-time during summer on a project to investigate the effects of selective androgen receptor modulators on skeletal muscle. Admitted to Pharm.D. program in Fall 2004.

Alysha Taxter, Fall 2003 to Spring 2004. Third Place Poster Presentation at Denman Undergraduate Research Forum 2004. Senior biology student. Worked on senior Honor's project to examine the effect of lysophospholipid analogs on prostate cancer cell growth. Admitted to M.D. program at Wright State University in Fall 2004.

Steven Kraynik, Summer and Fall 2004. Junior/senior undergraduate student in biochemistry. Worked full-time during the summer on a project to investigate the structure and function of the human androgen receptor.

Matthew Dellaquila, Fall 2004 to present. Junior undergraduate student in pharmaceutical sciences. Worked on a project to examine the structure-activity relationships and the effects of selective androgen receptor modulators on spermatogenesis.

Elodie Dempah, Summer 2004, Summer 2005. Freshman and sophomore undergraduate student from Spellman College, Atlanta, GA. Worked full-time on a project to examine the in vitro pharmacologic activity of phospholipids growth factor antagonists.

Rachel Leslie, Summer 2005. Senior undergraduate student from Ashland University, KY. Worked full-time on a project to examine the in vitro pharmacologic activity of a novel slective androgen receptor modulator.

Nicholas Bradley, Summer 2005. Sophomore undergraduate student in BSPS program. Worked full-time on a project to examine the in vitro and in vivo pharmacologic activity of a series of novel bis-indoles for cancer.

Kimberly Becker, Winter 2005, Spring 2005. Senior undergraduate student in BSPS program. Working full-time on a project to examine the in vitro and in vivo metabolism and pharmacokinetics of a series of anti-parasitic agents.

Stacy Baker, Linda Tran, Ivy Muteithia, Katie Albanese, Summer 2005-Spring 2006. Undergraduate students in the BSPS program. Working on various projects to examine the in vitro anti-cancer activity of series of tubulin antagonists, the clinical pharmacology of flavopiridol and the molecular pharmacology of SARMs.

Gina Sun, Kendall Whitt, Mara Dalton (Summer 2012) and Laura Kish, Zachary Sherman, Patrick Sweeney (Summer 2013). Summer interns at GTx, Inc. Working on various projects related to in vitro and in vivo pharmacologic activity of tubulin antagonists, AKR1C3 antagonists, and estrogen receptor α and β agonists and antagonists.